STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 155280

TO:	From:
Shailendra Kumar **Location: 5c03 / 5c18** **Thursday, June 09, 2005** **Art Unit: 1621** **Phone: 571-272-0640** **Serial Number: 10 / 508791**	**Jan Delaval** **Location: Biotech-Chem Library** **Remsen 1a51** **Phone: 571-272-2504** **jan.delaval@uspto.gov**

Search Notes

Jan please

FOR OFFICIAL USE ONLY

ACCESS DB # 155280

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: S. Kumar Examiner #: 69594 Date: 6/2/05

Art Unit: 1621 Phone Number: 2-0640 Serial Number: ~~10/927,493~~ 10/508,741

Location (Bldg/Room#): REM (Mailbox #): 5C18 Results Format Preferred (circle): PAPER DISK

5C03

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Amide compounds and method of using the same

Inventors (please provide full names): Scott K. Thomson

Earliest Priority Date: 3/27/02

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only ***Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.***



Z is CH, CR or N)

Y is O, S, NR and (CR^4R^5)

W1 is alkyl etc.

W2 is H, Halo, alkyl etc.

W3 is H, Halo, alkyl etc.

Q is cycloalkyl, Ar, Het

R^1, R^2 are H, Halo alkyl etc.

R^3 " " "

R^4, R^5, R^6 R^7 " " "

R^8 R^9 H, alkyl, Halo e

R^{10} R^{11} H " Ar, e

R^{12} is H, alkyl, etc.

R^{13}, R^{14} are H, "

****

STAFF USE ONLY

Searcher: [signature]

Searcher Phone #: 22504

Searcher Location: _____

Date Searcher Picked Up: 6/9/05

Date Completed: 6/9/05

Searcher Prep & Review Time: 25

Online Time: 155

Type of Search

_____ NA Sequence (#)

_____ AA Sequence (#)

✓ Structure (#)

_____ Bibliographic

_____ Litigation

_____ Fulltext

_____ Other

Vendors and cost where applicable

✓ STN _____ Dialog

_____ Questel/Orbit _____ Lexis/Nexis

_____ Westlaw _____ WWW/Internet

___ In-house sequence systems

___ Commercial ___ Oligomer ___ Score/Length

___ Interference ___ SPDI ___ Encode/Transl

_____ Other (specify)

```
=> d his

     (FILE 'HOME' ENTERED AT 13:16:49 ON 09 JUN 2005)
               DEL HIS

     FILE 'HCAPLUS' ENTERED AT 13:17:26 ON 09 JUN 2005
L1             1 S US20050107444/PN OR (US2004-508791# OR WO2003-US09461 OR US20
               E THOMPSON S/AU
L2            99 S E3,E19
               E THROMPSON SCOTT/AU
               E THOMPSON SCOTT/AU
L3            75 S E3,E10,E11
               E FRAZEE J/AU
L4            36 S E3,E9,E11,E12
               E KALLANDER L/AU
L5            14 S E4-E6
               E SCHWARTZ L/AU
L6           251 S E3-E13
               E MA C/AU
L7           502 S E3-E31
L8           839 S MA CHUN?/AU
               E MARINO J/AU
L9           140 S E3,E7,E36,E38-E41
               E NEEB M/AU
L10           85 S E3,E8,E9
               E WANG N/AU
L11         1263 S E3-E26 OR WANG NING?/AU

     FILE 'REGISTRY' ENTERED AT 13:21:54 ON 09 JUN 2005

     FILE 'HCAPLUS' ENTERED AT 13:21:54 ON 09 JUN 2005
               SET SMARTSELECT ON
L12          SEL L1 1- RN :     193 TERMS
               SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 13:21:55 ON 09 JUN 2005
L13           193 S L12
L14               STR
L15             0 S L14
L16           136 S L13 AND NR>=2
L17            57 S L13 NOT L16
L18           115 S L16 AND N>=2
L19            21 S L16 NOT L18
L20           113 S L18 NOT SQL/FA
               SAV L20 KUMAR508/A

     FILE 'HCAOLD' ENTERED AT 13:28:50 ON 09 JUN 2005
L21             0 S L20

     FILE 'HCAPLUS' ENTERED AT 13:28:53 ON 09 JUN 2005
L22             3 S L20
L23             2 S L22 AND L1-L11
L24             3 S L22 AND (GLAXO? OR SMITH? OR KLINE? OR BEECHAM?)/PA,CS
L25             3 S L22-L24

     FILE 'USPATFULL, USPAT2' ENTERED AT 13:29:51 ON 09 JUN 2005
L26             1 S L20

=> fil uspatall
FILE 'USPATFULL' ENTERED AT 13:30:15 ON 09 JUN 2005
```

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:30:15 ON 09 JUN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l26 bib abs hitrn fhitstr

L26 ANSWER 1 OF 1 USPATFULL on STN
AN 2005:125054 USPATFULL
TI Amide compounds and methods of using the same
IN Thompsom, Scott K, King of Prussia, PA, UNITED STATES
Frazee, James S., King of Prussia, PA, UNITED STATES
Kallander, Lara S., King of Prussia, PA, UNITED STATES
Ma, Chun, Edgewater, NJ, UNITED STATES
Marino, Joseph P., King of Prussia, PA, UNITED STATES
Neeb, Michael J., King of Prussia, PA, UNITED STATES
Wang, Ning, King of Prussia, PA, UNITED STATES
PI US 2005107444 A1 20050519
AI US 2003-508791 A1 20030326 (10)
WO 2003-US9461 20030326
PRAI US 2003-368427P 20020327 (60)
DT Utility
FS APPLICATION
LREP SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US, UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939, US
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4203
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a compound having the formula ##STR1## pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **609772-12-5P** **612498-89-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((S)-2-phenylpropyl)amino]propoxy]phenyl]-1-morpholin-4-ylethanone **612498-99-4P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-morpholin-4-ylethanone hydrochloride **612499-00-0P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-(4-methylpiperazin-1-yl)ethanone hydrochloride **612499-01-1P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N-methylacetamide hydrochloride **612499-02-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(1H-imidazol-2-yl)methyl]acetamide hydrochloride **612499-03-3P**, N-[(5-Bromothiophen-2-yl)methyl]-2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]acetamide hydrochloride **612499-05-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(thiophen-2-yl)methyl]acetamide hydrochloride **612499-06-6P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N-ethylacetamide hydrochloride **612499-07-7P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-dimethylacetamide hydrochloride **612499-08-8P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-

diphenylethyl)amino]propoxy]phenyl]-1-pyrrolidin-1-ylethanone hydrochloride **612499-09-9P**, (R)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methylpropoxy]phenyl]-1-morpholin-4-ylethanone hydrochloride **612499-10-2P**, (R)-2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]butoxy]phenyl]-1-morpholin-4-ylethanone hydrochloride **612499-11-3P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-(4-methylpiperazin-1-yl)ethanone **612499-12-4P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N-methylacetamide **690955-08-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(1H-imidazol-2-yl)methyl]acetamide **691892-53-2P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-piperidin-1-ylethanone hydrochloride **691892-54-3P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-diethylacetamide hydrochloride **691892-55-4P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-[azetidin-1-yl]ethanone hydrochloride **691892-56-5P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-[azepan-1-yl]ethanone hydrochloride **691892-65-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-methoxyethyl)acetamide hydrochloride **691892-67-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-dimethylaminoethyl)acetamide hydrochloride **691892-68-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(morpholin-4-yl)ethyl]acetamide hydrochloride **691892-69-0P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-methoxy-1-methylethyl)acetamide hydrochloride **691892-70-3P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-methoxyethyl)-N-methylacetamide hydrochloride **691892-71-4P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-bis(2-methoxyethyl)acetamide hydrochloride **691892-72-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(furan-2-yl)methyl]acetamide hydrochloride **691892-73-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(3-methylisoxazol-5-yl)methyl]acetamide hydrochloride **691892-74-7P** **691892-75-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(pyrrolidin-1-yl)ethyl]acetamide hydrochloride **691892-76-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(pyridin-3-yl)methyl]acetamide hydrochloride **691892-77-0P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(pyridin-2-yl)ethyl]acetamide hydrochloride **691892-78-1P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(phenoxy)ethyl]acetamide hydrochloride **691892-79-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[3-(isopropoxy)propyl]acetamide hydrochloride **691892-80-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(3-methoxypropyl)acetamide hydrochloride **691892-81-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]acetamide hydrochloride **691892-82-7P**,

2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(4-methylthiazol-2-yl)methyl]acetamide hydrochloride **691892-83-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[1-(thiophen-2-yl)ethyl]acetamide hydrochloride **691892-86-1P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(thiophen-3-yl)methyl]acetamide hydrochloride **691892-89-4P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(5-methyl-4H-1,2,4-triazol-3-yl)methyl]acetamide hydrochloride **691892-92-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(pyridin-2-yl)methyl]acetamide hydrochloride **691892-95-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(tetrahydrofuran-2-yl)methyl]acetamide hydrochloride **691892-98-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(1-ethylpyrrolidin-2-yl)methyl]acetamide hydrochloride **691893-01-3P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-octylacetamide hydrochloride **691893-04-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-decylacetamide hydrochloride **691893-07-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide hydrochloride **691893-12-6P**, 2-[[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]-2-(thiophen-2-yl)acetic acid hydrochloride **691893-15-9P**, 3-[[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]propionic acid hydrochloride **691893-22-8P**, [2-[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]acetic acid hydrochloride **691893-40-0P**, 4-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]-N,N-dimethylbenzamide **691893-47-7P**, 1-[4-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-1-morpholin-4-ylmethanone **691893-48-8P**, 1-[4-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-1-(4-methylpiperazin-1-yl)methanone **691893-49-9P**, 3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]-N,N-dimethylbenzamide **691893-50-2P**, 3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]-N-phenylbenzamide **691893-51-3P**, 1-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-1-morpholin-4-ylmethanone **691893-52-4P**, 1-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-1-(4-methylpiperazin-1-yl)methanone **691893-53-5P**, N-[1-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]methanoyl]methanesulfonamide **691893-54-6P**, N-[1-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]methanoyl]benzenesulfonamide **691893-55-7P**, N-[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]methanesulfonamide **691893-56-8P**, N-[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]benzenesulfonamide **691893-57-9P**, N-[-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]-N-methylbenzenesulfonamide **691893-58-0P**, N-[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]-N-methylmethanesulfonamide **691893-59-1P 691893-60-4P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((S)-2-phenylpropyl)amino]propoxy]phenyl]-N-

ethylacetamide hydrochloride **691893-61-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((R)-2-phenylpropyl)amino]propoxy]phenyl]-N,N-dimethylacetamide **691893-62-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((R)-2-phenylpropyl)amino]propoxy]phenyl]acetamide hydrochloride **691893-63-7P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((R)-2-phenylpropyl)amino]propoxy]phenyl]-N-methylacetamide hydrochloride **691893-64-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((R)-2-phenylpropyl)amino]propoxy]phenyl]-N,N-dimethylacetamide hydrochloride **691893-65-9P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-morpholin-4-ylethanone **691893-66-0P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-dimethylacetamide **691893-67-1P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-piperidin-1-ylethanone **691893-68-2P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-pyrrolidin-1-ylethanone **691893-69-3P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N-ethylacetamide **691893-70-6P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-diethylacetamide **691893-71-7P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-azetidin-1-ylethanone **691893-72-8P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-azepan-1-ylethanone **691893-73-9P**, N-(5-Bromothiophen-2-ylmethyl)-2-[3-[3-[(2-chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]acetamide **691893-74-0P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(thiophen-2-yl)methyl]acetamide **691893-75-1P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-methoxyethyl)acetamide **691893-76-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-dimethylaminoethyl)acetamide **691893-78-4P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-(morpholin-4-yl)ethyl)acetamide **691893-80-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-methoxy-1-methylethyl)acetamide **691893-82-0P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-methoxyethyl)-N-methylacetamide **691893-84-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-bis(2-methoxyethyl)acetamide **691893-86-4P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(furan-2-yl)methyl]acetamide **691893-87-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(3-methylisoxazol-5-ylmethyl)acetamide **691893-88-6P** **691893-89-7P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(pyrrolidin-1-yl)ethyl]acetamide **691893-90-0P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(pyridin-3-yl)methyl]acetamide **691893-91-1P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(pyridin-2-yl)ethyl]acetamide **691893-92-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(phenoxy)ethyl]acetamide **691893-93-3P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(3-isopropoxypropyl)acetamide **691893-94-4P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(3-methoxypropyl)acetamide **691893-95-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(5-methyl-1,3,4-oxadiazol-2-

yl)methyl]acetamide **691893-96-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(4-methylthiazol-2-yl)methyl]acetamide **691893-97-7P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[1-(thiophen-2-yl)ethyl]acetamide **691893-98-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(thiophen-3-yl)methyl]acetamide **691893-99-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(5-methyl-4H-1,2,4-triazol-3-yl)methyl]acetamide **691894-00-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(pyridin-2-yl)methyl]acetamide **691894-01-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(tetrahydrofuran-2-yl)methyl]acetamide **691894-02-7P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(1-ethylpyrrolidin-2-yl)methyl]acetamide **691894-03-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-octylacetamide **691894-04-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-decylacetamide **691894-05-0P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide **691894-06-1P**, [[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]-2-(thiophen-2-yl)acetic acid **691894-07-2P**, 3-[[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]propionic acid **691894-08-3P**, [3-[2-[3-[3-[(2-Chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]acetic acid **691894-09-4P**, (R)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methylpropoxy]phenyl]-1-morpholin-4-ylethanone **691894-10-7P**, (R)-2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]butoxy]phenyl]-1-(morpholin-4-yl)ethanone **691894-11-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((S)-2-phenylpropyl)amino]propoxy]phenyl]-N-ethylacetamide **691894-12-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((R)-2-phenylpropyl)amino]propoxy]phenyl]acetamide **691894-13-0P**

(amide compds. and methods of using the same)

IT **691893-18-2P**, 3-[[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]propionic acid tert-butyl ester

(amide compds. and methods of using the same)

IT **609772-12-5P**

(amide compds. and methods of using the same)

RN 609772-12-5 USPATFULL

CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 13:31:29 ON 09 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 9 Jun 2005 VOL 142 ISS 24
FILE LAST UPDATED: 8 Jun 2005 (20050608/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d l25 all fhitstr tot

L25 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:430788 HCAPLUS
DN 141:6921
ED Entered STN: 27 May 2004
TI Preparation of substituted phenyl amides as LXRα and LXRβ agonists
IN **Thompson, Scott K.; Frazee, James S.; Kallander, Lara S.; Ma, Chun; Marino, Joseph P.; Neeb, Michael J.; Wang, Ning**
PA **Smithkline Beecham Corporation, USA**
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D265-30
ICS C07D295-06; C07D211-06; C07D241-04; C07D207-08; C07C233-05;
C07C311-15; A61K031-535; A61K031-165; A61K031-445; A61K031-495;

A61K031-40; A61K031-395; A61K031-55; A61K031-18; A61K031-16
CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004043939	A1	20040527	WO 2003-US9461	20030326 <--
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1497270	A1	20050119	EP 2003-716872	20030326 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005107444	A1	20050519	US 2003-508791	20030326 <--
PRAI US 2002-368427P	P	20020327 <--		
WO 2003-US9461	W	20030326 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004043939	ICM	C07D265-30
	ICS	C07D295-06; C07D211-06; C07D241-04; C07D207-08; C07C233-05; C07C311-15; A61K031-535; A61K031-165; A61K031-445; A61K031-495; A61K031-40; A61K031-395; A61K031-55; A61K031-18; A61K031-16
WO 2004043939	ECLA	C07C235/34; C07C235/46; C07C311/51; C07D205/04; C07D207/09; C07D213/38; C07D213/40B; C07D223/04; C07D233/24; C07D233/54C2D4; C07D249/08C2D; C07D261/08; C07D271/10B; C07D277/28; C07D295/12B1D2; C07D295/18B1D; C07D295/18B2D; C07D307/14; C07D307/52; C07D333/20; C07D333/38 <--
US 2005107444	NCL	514/345.000; 514/352.000; 514/357.000; 514/618.000; 514/619.000; 514/620.000; 546/291.000; 546/309.000; 546/336.000; 564/162.000 <--

OS MARPAT 141:6921
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Z = C(H, alkyl, etc.), N; k = 0-4; t = 0-1; Y = O, S, amino, alkyl; W1 = alkyl, cycloalkyl, aryl, etc.; W2 = H, halo, alk(en/yn)yl, etc.; W3 = H, halo, alkyl, etc.; Q = cycloalkyl, aryl, heteroaryl; p = 0-8; n = 2-8; m, q, t = 0-1; R1-2 = H, halo, alk(en/yn)yl, etc.; R4-11 = H, halo, alkyl, etc.] are prepared For instance, Me [3-(3-bromopropoxy)phenyl]acetate (preparation given) is reacted with N-[2-chloro-3-(trifluoromethyl)benzyl]-2,2-diphenylethaneamine (preparation given; CH3CN, K2CO3, reflux, 4 days), the resulting amine saponified (THF/H2O, LiOH) and the acid coupled to morpholine (CH3CN, BOPCl, Et3N) to give II. I are useful as LXR agonists.
ST phenyl amide LXR receptor agonist prepn
IT Steroid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LXR (liver X receptor); amide compds. and methods of using the same)

IT Anti-inflammatory agents
Anticholesteremic agents
Atherosclerosis
Cardiovascular agents
Human
Inflammation
(amide compds. and methods of using the same)

IT Antiarteriosclerotics
(antiatherosclerotics; amide compds. and methods of using the same)

IT **609772-12-5P 612498-89-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((S)-2-phenylpropyl)amino]propoxy]phenyl]-1-morpholin-4-ylethanone **612498-99-4P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-morpholin-4-ylethanone hydrochloride **612499-00-0P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-(4-methylpiperazin-1-yl)ethanone hydrochloride **612499-01-1P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N-methylacetamide hydrochloride **612499-02-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(1H-imidazol-2-yl)methyl]acetamide hydrochloride **612499-03-3P**, N-[(5-Bromothiophen-2-yl)methyl]-2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]acetamide hydrochloride **612499-05-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(thiophen-2-yl)methyl]acetamide hydrochloride **612499-06-6P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N-ethylacetamide hydrochloride **612499-07-7P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-dimethylacetamide hydrochloride **612499-08-8P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-pyrrolidin-1-ylethanone hydrochloride **612499-09-9P**, (R)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methylpropoxy]phenyl]-1-morpholin-4-ylethanone hydrochloride **612499-10-2P**, (R)-2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]butoxy]phenyl]-1-morpholin-4-ylethanone hydrochloride **612499-11-3P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-(4-methylpiperazin-1-yl)ethanone **612499-12-4P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N-methylacetamide **690955-08-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(1H-imidazol-2-yl)methyl]acetamide **691892-53-2P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-piperidin-1-ylethanone hydrochloride **691892-54-3P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-diethylacetamide hydrochloride **691892-55-4P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-[azetidin-1-yl]ethanone hydrochloride **691892-56-5P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-[azepan-1-yl]ethanone hydrochloride **691892-65-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-methoxyethyl)acetamide hydrochloride **691892-67-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-dimethylaminoethyl)acetamide hydrochloride **691892-68-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(morpholin-4-yl)ethyl]acetamide hydrochloride **691892-69-0P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-

diphenylethyl)amino]propoxy]phenyl]-N-(2-methoxy-1-methylethyl)acetamide hydrochloride **691892-70-3P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-methoxyethyl)-N-methylacetamide hydrochloride **691892-71-4P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-bis(2-methoxyethyl)acetamide hydrochloride **691892-72-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(furan-2-yl)methyl]acetamide hydrochloride **691892-73-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(3-methylisoxazol-5-yl)methyl]acetamide hydrochloride **691892-74-7P** **691892-75-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(pyrrolidin-1-yl)ethyl]acetamide hydrochloride **691892-76-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(pyridin-3-yl)methyl]acetamide hydrochloride **691892-77-0P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(pyridin-2-yl)ethyl]acetamide hydrochloride **691892-78-1P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(phenoxy)ethyl]acetamide hydrochloride **691892-79-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[3-(isopropoxy)propyl]acetamide hydrochloride **691892-80-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(3-methoxypropyl)acetamide hydrochloride **691892-81-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]acetamide hydrochloride **691892-82-7P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(4-methylthiazol-2-yl)methyl]acetamide hydrochloride **691892-83-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[1-(thiophen-2-yl)ethyl]acetamide hydrochloride **691892-86-1P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(thiophen-3-yl)methyl]acetamide hydrochloride **691892-89-4P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(5-methyl-4H-1,2,4-triazol-3-yl)methyl]acetamide hydrochloride **691892-92-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(pyridin-2-yl)methyl]acetamide hydrochloride **691892-95-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(tetrahydrofuran-2-yl)methyl]acetamide hydrochloride **691892-98-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(1-ethylpyrrolidin-2-yl)methyl]acetamide hydrochloride **691893-01-3P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-octylacetamide hydrochloride **691893-04-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-decylacetamide hydrochloride **691893-07-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide hydrochloride **691893-12-6P**, 2-[[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]-2-(thiophen-2-yl)acetic acid hydrochloride **691893-15-9P**, 3-[[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]propionic acid

hydrochloride **691893-22-8P**, [2-[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]acetic acid hydrochloride **691893-40-0P**, 4-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]-N,N-dimethylbenzamide **691893-47-7P**, 1-[4-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-1-morpholin-4-ylmethanone **691893-48-8P**, 1-[4-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-1-(4-methylpiperazin-1-yl)methanone **691893-49-9P**, 3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]-N,N-dimethylbenzamide **691893-50-2P**, 3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]-N-phenylbenzamide **691893-51-3P**, 1-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-1-morpholin-4-ylmethanone **691893-52-4P**, 1-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-1-(4-methylpiperazin-1-yl)methanone **691893-53-5P**, N-[1-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]methanoyl]methanesulfonamide **691893-54-6P**, N-[1-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]methanoyl]benzenesulfonamide **691893-55-7P**, N-[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]methanesulfonamide **691893-56-8P**, N-[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]benzenesulfonamide **691893-57-9P**, N-[-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]-N-methylbenzenesulfonamide **691893-58-0P**, N-[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]-N-methylmethanesulfonamide **691893-59-1P 691893-60-4P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((S)-2-phenylpropyl)amino]propoxy]phenyl]-N-ethylacetamide hydrochloride **691893-61-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((R)-2-phenylpropyl)amino]propoxy]phenyl]-N,N-dimethylacetamide **691893-62-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((R)-2-phenylpropyl)amino]propoxy]phenyl]acetamide hydrochloride **691893-63-7P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((R)-2-phenylpropyl)amino]propoxy]phenyl]-N-methylacetamide hydrochloride **691893-64-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((R)-2-phenylpropyl)amino]propoxy]phenyl]-N,N-dimethylacetamide hydrochloride **691893-65-9P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-morpholin-4-ylethanone **691893-66-0P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-dimethylacetamide **691893-67-1P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-piperidin-1-ylethanone **691893-68-2P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-pyrrolidin-1-ylethanone **691893-69-3P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N-ethylacetamide **691893-70-6P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-diethylacetamide **691893-71-7P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-azetidin-1-ylethanone **691893-72-8P**, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-azepan-1-ylethanone **691893-73-9P**, N-(5-Bromothiophen-2-ylmethyl)-2-[3-[3-[(2-chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]acetamide **691893-74-0P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(thiophen-2-yl)methyl]acetamide **691893-75-1P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-

diphenylethyl)amino]propoxy]phenyl]-N-(2-methoxyethyl)acetamide **691893-76-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-dimethylaminoethyl)acetamide **691893-78-4P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-(morpholin-4-yl)ethyl)acetamide **691893-80-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-methoxy-1-methylethyl)acetamide **691893-82-0P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(2-methoxyethyl)-N-methylacetamide **691893-84-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-bis(2-methoxyethyl)acetamide **691893-86-4P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(furan-2-yl)methyl]acetamide **691893-87-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(3-methylisoxazol-5-ylmethyl)acetamide **691893-88-6P 691893-89-7P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(pyrrolidin-1-yl)ethyl]acetamide **691893-90-0P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(pyridin-3-yl)methyl]acetamide **691893-91-1P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(pyridin-2-yl)ethyl]acetamide **691893-92-2P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(phenoxy)ethyl]acetamide **691893-93-3P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(3-isopropoxypropyl)acetamide **691893-94-4P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-(3-methoxypropyl)acetamide **691893-95-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]acetamide **691893-96-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(4-methylthiazol-2-yl)methyl]acetamide **691893-97-7P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[1-(thiophen-2-yl)ethyl]acetamide **691893-98-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(thiophen-3-yl)methyl]acetamide **691893-99-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(5-methyl-4H-1,2,4-triazol-3-yl)methyl]acetamide **691894-00-5P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(pyridin-2-yl)methyl]acetamide **691894-01-6P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(tetrahydrofuran-2-yl)methyl]acetamide **691894-02-7P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(1-ethylpyrrolidin-2-yl)methyl]acetamide **691894-03-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-octylacetamide **691894-04-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-decylacetamide **691894-05-0P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[2-(2-hydroxyethoxy)ethyl]acetamide **691894-06-1P**, [[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]-2-(thiophen-2-yl)acetic acid **691894-07-2P**, 3-[[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]propionic acid **691894-08-3P**, [3-[2-[3-[3-[(2-Chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]acetic acid **691894-09-4P**, (R)-2-[3-[3-[[2-Chloro-3-

(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methylpropoxy]phenyl]-1-morpholin-4-ylethanone **691894-10-7P**, (R)-2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]butoxy]phenyl]-1-(morpholin-4-yl)ethanone **691894-11-8P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((S)-2-phenylpropyl)amino]propoxy]phenyl]-N-ethylacetamide **691894-12-9P**, 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((R)-2-phenylpropyl)amino]propoxy]phenyl]acetamide **691894-13-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amide compds. and methods of using the same)

IT 62-53-3, Aniline, reactions 98-10-2, Benzenesulfonamide 99-76-3, 4-Hydroxybenzoic acid methyl ester 108-00-9, N,N-Dimethylethane-1,2-diamine 109-01-3 109-85-3, 2-Methoxyethylamine 109-89-7, Diethylamine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 111-86-4, Octylamine 111-95-5 123-75-1, Pyrrolidine, reactions 503-29-7, Azetidine 617-89-0, [(Furan-2-yl)methyl]amine 621-37-4, (3-Hydroxyphenyl)acetic acid 627-18-9 929-06-6, 2-(2-Aminoethoxy)ethanol 1184-85-6, N-Methylmethanesulfonamide 1758-46-9, 2-(Phenoxy)ethylamine 2016-57-1, Decylamine 2038-03-1, 2-(Morpholin-4-yl)ethylamine 2706-56-1, 2-(Pyridin-2-yl)ethylamine 2906-12-9, 3-Isopropoxypropylamine 3144-09-0, Methylsulfonamide 3731-51-9, [(Pyridin-2-yl)methyl]amine 3731-52-0, [(Pyridin-3-yl)methyl]amine 3963-62-0, 2,2-Diphenethylamine 4795-29-3, [(Tetrahydrofuran-2-yl)methyl]amine 5183-78-8, N-Methylbenzenesulfonamide 5332-73-0, 3-Methoxypropylamine 6309-16-6, 1-(Thiophen-2-yl)ethylamine 7154-73-6, 2-(Pyrrolidin-1-yl)ethylamine 17596-79-1, (S)-2-Phenylpropylamine 19438-10-9, 3-Hydroxybenzoic acid methyl ester 21124-40-3 24621-61-2, (S)-1,3-Butanediol 26116-12-1, [(1-Ethylpyrrolidin-2-yl)methyl]amine 27532-96-3, 2-Aminoacetic acid tert-butyl ester hydrochloride 27757-85-3, [(Thiophen-2-yl)methyl]amine 27757-86-4, [(Thiophen-3-yl)methyl]amine 28163-64-6, (R)-2-Phenylpropylamine 37143-54-7, 2-Methoxy-1-methylethylamine 38256-93-8, (2-Methoxyethyl)methylamine 51221-45-5, [(4-Methylthiazol-2-yl)methyl]amine 53332-80-2, [(1H-Imidazol-2-yl)methyl]amine 53515-36-9, 2-(Thiomorpholin-4-yl)ethylamine 58620-93-2, 3-Aminopropionic acid tert-butyl ester hydrochloride 93118-03-7, 2-Chloro-3-trifluoromethylbenzaldehyde 98244-48-5, (S)-(+)-3-Bromo-2-methyl-1-propanol 125295-22-9, [(5-Methyl-1,3,4-oxadiazol-2-yl)methyl]amine 131052-49-8, [(5-Methyl-4H-1,2,4-triazol-3-yl)methyl]amine 154016-55-4, [(3-Methylisoxazol-5-yl)methyl]amine 405911-09-3 610318-50-8, (R)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methylpropoxy]phenyl]acetic acid 610318-54-2, (R)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-3-methylpropoxy]phenyl]acetic acid 612499-04-4, [(5-Bromothiophen-2-yl)methyl]amine
RL: RCT (Reactant); RACT (Reactant or reagent)
(amide compds. and methods of using the same)

IT 42058-59-3P, Methyl 3-hydroxyphenylacetate 82614-88-8P, Toluene-4-sulfonic acid (S)-3-hydroxybutyl ester 228579-12-2P, Methyl [3-(3-bromopropoxy)phenyl]acetate 405911-17-3P, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetic acid hydrochloride 405911-26-4P, Methyl [3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetate 405911-35-5P 609772-13-6P 609772-14-7P, (S)-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-phenylpropyl)amino]propoxy]phenyl]acetic acid methyl ester 609772-15-8P, (S)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-phenylpropyl)amino]propoxy]phenyl]acetic acid

609772-16-9P, (S)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-phenylpropyl)amino]propoxy]phenyl]acetic acid hydrochloride
610317-98-1P, (R)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methylpropoxy]phenyl]acetic acid methyl ester
610317-99-2P, (R)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methylpropoxy]phenyl]acetic acid hydrochloride
610318-03-1P, (R)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-3-methylpropoxy]phenyl]acetic acid hydrochloride
610318-97-3P, (S)-[3-(2-Methyl-3-bromopropoxy)phenyl]acetic acid methyl ester 610318-99-5P, (S)-[3-(3-Hydroxybutoxy)phenyl]acetic acid methyl ester 610319-00-1P, (S)-[3-[3-((Toluene-4-sulfonyl)oxy)butoxy]phenyl]acetic acid methyl ester 610319-01-2P, (R)-2-[3-[3-[(2,2-Diphenylethyl)amino]-3-methylpropoxy]phenyl]acetic acid methyl ester
610319-02-3P, (R)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-3-methylpropoxy]phenyl]acetic acid methyl ester
610319-03-4P, N-(2,2-Diphenylethyl)-N-(3-hydroxypropyl)-N-(2-chloro-3-trifluoromethylbenzyl)amine **691893-18-2P**, 3-[[2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]ethanoyl]amino]propionic acid tert-butyl ester 691893-43-3P, 4-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]benzoic acid methyl ester 691893-45-5P, 4-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]benzoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(amide compds. and methods of using the same)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition of absorption; amide compds. and methods of using the same)

IT 278596-98-8 363593-56-0
RL: PRP (Properties)
(unclaimed sequence; preparation of substituted Ph amides as LXRα and LXRβ agonists)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Glaxo Group Limited; WO 0224632 A2 2002 HCAPLUS

IT **609772-12-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amide compds. and methods of using the same)

RN 609772-12-5 HCAPLUS
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:796427 HCAPLUS
DN 139:323535
ED Entered STN: 10 Oct 2003
TI Preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivatives as modulating agents for liver X receptors (LXR)
IN **Thompson, Scott K.**; **Frazee, James S.**; **Kallander, Lara S.**; **Ma, Chun**; **Marino, Joseph P.**; **Neeb, Michael J.**; Bhat, Ajita; Mcatee, John Jeffrey; Stavenger, Robert A.
PA **Smithkline Beecham Corporation, USA**
SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003082205	A2	20031009	WO 2003-US9450	20030326
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005113580	A1	20050526	US 2003-508894	20030326
PRAI US 2002-368425P	P	20020327		
WO 2003-US9450	W	20030326		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003082205	ICM	A61K
US 2005113580	NCL	546/268.100; 546/335.000; 560/024.000; 562/043.000; 558/410.000; 562/450.000

OS MARPAT 139:323535
GI



AB The title compds. (I) [X = C1-8 alkyl, halo, each (un)substituted OH, NH2, NHCONH2, SO2NH2, CO2H, or C(:NH)NH2, 5 or 6-membered heterocyclyl, etc.; or X and R3 together with their bonded atoms form alkylenedioxy; Z = (un)substituted CH or N; when Z = (un)substituted CH, p1 = 0-4 and q1 =

0-1; when Z = N, p1 = 0-3 and q1 = 0; Y = O, S, each (un)substituted NH or CH2; W1 = C1-6 alkyl, C3-8 cycloalkyl, aryl, heterocyclyl, etc.; W2 = H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, each N, S, or O-(un)substituted C0-6 alkyl-NH2, C0-C6 alkyl-SH, C0-6 alkyl-OH, C0-6 alkyl-CO2H, etc.; W3 = H, halo, C1-6 alkyl, each N, S, or O-(un)substituted C0-6 alkyl-NH2, C0-6 alkyl-SH, C0-6 alkyl-OH, or C0-6 alkyl-CO2H, etc.; p = 0-8; n = 2-8; m, q, q1 = 0, 1; R1, R2 = H, halo, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, each N-, O-, or S-(un)substituted C0-6 alkyl-NH2 C0-6 alkyl-OH, or C0-6 alkyl-SH, heterocyclyl-C1-C6 alkyl, aryl-C1-6 alkyl, C3-7 cycloalkyl-C1-C6 alkyl, etc.; or CR1R2 forms a 3-5 membered carbocyclic or heterocyclic ring; R3 = halo, cyano, nitro, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, aryl-C0-6 alkyl, heterocyclyl-C0-6 alkyl etc.; R4, R5 = H, halo, C1-6 alkyl, heterocyclyl-C0-6 alkyl, aryl-C0-6 alkyl, C3-7 cycloalkyl-C0-6 alkyl; R6, R7, R8, R9 = H, halo, C1-6 alkyl, heterocyclyl-C0-6 alkyl, aryl-C0-6 alkyl, C3-7 cycloalkyl-C0-6 alkyl, etc.] or pharmaceutically acceptable salts or solvates thereof are prepared Many specific compds. are claimed. Also disclosed are pharmaceutical compns. containing the compds. I. The compds. I, salts and solvates of this invention are useful as LXR agonists for the prevention or treatment of LXR-mediated diseases such as cardiovascular disease, atherosclerosis, inflammation or as a medicament for increasing reverse cholesterol transport or inhibiting cholesterol absorption.

ST phenoxypropylbenzylamine prepn agonist liver X receptor; pyridyloxypropylbenzylamine prepn modulator LXR; cardiovascular disease treatment prevention phenoxypropylbenzylamine pyridyloxypropylbenzylamine prepn; atherosclerosis treatment prevention phenoxypropylbenzylamine pyridyloxypropylbenzylamine prepn; inflammation treatment prevention phenoxypropylbenzylamine pyridyloxypropylbenzylamine prepn

IT Steroid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LXR (liver X receptor); preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

IT Anti-inflammatory agents
Atherosclerosis
Cardiovascular agents
Cardiovascular system, disease
Inflammation
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(increasing reverse cholesterol transport or inhibiting cholesterol absorption; preparation of [3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR))

IT 609772-07-8P 609772-11-4P 612498-41-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

IT 393-49-7P, 2-Trifluoromethyl-5-nitroaniline 632-02-0P 938-95-4P, 2-(4-Chlorophenyl)propionic acid 942-54-1P, 2-(4-Methoxyphenyl)propionic acid 2184-85-2P 4442-83-5P, 2-Cyclohexyl-2-phenylethanol 4442-89-1P

13027-73-1P 13062-93-6P, 2-(4-Methoxyphenyl)propylamine hydrochloride
14320-58-2P 19962-06-2P 20334-70-7P, 2-(3-Chlorophenyl)propionic acid
25912-16-7P, 3-Pyrrolidin-1-ylphenol 28387-66-8P 30988-91-1P
31007-10-0P 32040-07-6P, 1-(3-Methoxyphenyl)pyrrolidine 35022-33-4P,
Methyl 2,2-dimethyl-3-(3-hydroxyphenyl)propionate 42058-59-3P, Methyl
3-hydroxyphenylacetate 58955-78-5P, N-Methyl-3-nitrobenzenesulfonamide
62969-42-0P, (3-Benzyloxyphenyl)acetic acid methyl ester 63362-05-0P
65292-90-2P 65857-58-1P 72551-60-1P 72551-61-2P 73415-84-6P
78103-77-2P, Methyl 2-phenyl-4-methyl-4-pentenoate 78592-82-2P
81270-37-3P 91061-46-0P 99329-55-2P, 4-(3-Methoxyphenyl)piperidine
99329-65-4P 99329-68-7P, 1-Benzyl-4-(3-methoxyphenyl)piperidin-4-ol
140232-81-1P 156450-01-0P 198627-86-0P 228579-12-2P, Methyl
[3-(3-bromopropoxy)phenyl]acetate 394202-85-8P 405910-78-3P
405911-17-3P 405911-26-4P 405911-35-5P 453560-74-2P 459434-40-3P
609772-10-3P 609772-14-7P 610317-98-1P 610317-99-2P 610318-03-1P
610318-44-0P 610318-97-3P 610318-99-5P 610319-00-1P 610319-01-2P
610319-02-3P 610319-03-4P 610319-19-2P 610319-22-7P 610319-23-8P
610319-24-9P 610319-26-1P 612498-25-6P 612498-26-7P 612498-27-8P
612498-28-9P 612498-29-0P 612498-30-3P 612498-31-4P 612498-32-5P
612498-33-6P 612498-34-7P 612498-35-8P 612498-36-9P 612498-40-5P
612498-42-7P 612498-43-8P 612498-44-9P, (2-Chloro-3-
trifluoromethylbenzyl)(2-cyclohexyl-2-phenylethyl)[3-[3-[(1-ethoxymethyl-
1H-1,2,3,4-tetrazol-5-yl)methyl]phenoxy]propyl]amine 612498-45-0P,
(2-Chloro-3-trifluoromethylbenzyl)(2-cyclohexyl-2-phenylethyl)[3-[3-[(2-
ethoxymethyl-2H-1,2,3,4-tetrazol-5-yl)methyl]phenoxy]propyl]amine
612498-47-2P 612498-48-3P 612498-49-4P 612498-50-7P 612498-51-8P
612498-52-9P 612498-53-0P 612498-54-1P 612498-55-2P 612498-56-3P
612498-57-4P 612498-58-5P 612498-59-6P 612498-60-9P 612498-62-1P
612498-63-2P 612498-64-3P 612498-65-4P 612498-66-5P 612498-67-6P
612498-68-7P 612498-69-8P 612498-70-1P 612498-71-2P 612498-72-3P
612498-73-4P 612498-74-5P 612498-75-6P 612498-76-7P 612498-77-8P
612498-79-0P 612498-80-3P 612498-82-5P 612498-83-6P 612498-84-7P
612498-86-9P 612498-87-0P 612498-88-1P **612498-89-2P**
612498-90-5P 612498-91-6P 612498-93-8P 612498-95-0P 612498-96-1P
612498-97-2P 612498-98-3P **612498-99-4P 612499-00-0P**
612499-01-1P 612499-02-2P 612499-03-3P
612499-05-5P 612499-06-6P, 2-[3-[3-[[2-Chloro-3-
(trifluoromethyl)benzyl]-(2,2-diphenylethyl)amino]propoxy]phenyl]-N-
ethylacetamide hydrochloride **612499-07-7P 612499-08-8P**
612499-09-9P 612499-10-2P 612499-13-5P 612499-14-6P
612499-15-7P 612499-16-8P 612499-17-9P 612499-18-0P 612499-19-1P
612499-20-4P 612499-21-5P 612499-22-6P 612499-23-7P 612499-25-9P
612499-26-0P 612499-27-1P 612499-28-2P 612499-29-3P 612499-30-6P
612499-31-7P 612499-32-8P 612499-33-9P 612499-34-0P 612499-35-1P
612499-36-2P 612499-37-3P 612499-38-4P 612499-39-5P 612499-40-8P
612499-41-9P 612499-42-0P 612499-43-1P 612499-44-2P 612499-55-5P
612499-56-6P 612499-57-7P 612499-58-8P 612499-59-9P 612499-60-2P
612499-61-3P 612499-62-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of N-[3-(2-pyridyloxy or
phenoxy)propyl]benzylamine derivs. as modulating agents for liver X
receptors (LXR) for prevention or treatment of LXR-mediated diseases)

IT 609772-09-0P 612498-39-2P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)
(intermediate; preparation of N-[3-(2-pyridyloxy or
phenoxy)propyl]benzylamine derivs. as modulating agents for liver X
receptors (LXR) for prevention or treatment of LXR-mediated diseases)

IT 612499-46-4P 612499-48-6P 612499-50-0P 612499-52-2P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

IT 612495-16-6P 612495-17-7P 612495-23-5P 612495-46-2P 612495-65-5P
612498-19-8P 612498-37-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

IT 36611-40-2P 36665-82-4P 68505-16-8P 74771-89-4P 78651-13-5P
78651-14-6P 80084-95-3P 80084-96-4P 83987-10-4P 83987-36-4P
83987-43-3P 83987-61-5P 93788-43-3P 217098-62-9P 217098-65-2P
317360-11-5P 329774-24-5P 329774-26-7P 329774-28-9P 609772-06-7P
609772-13-6P 609772-15-8P 609772-16-9P 612494-88-9P 612494-89-0P
612494-90-3P 612494-91-4P 612494-92-5P 612494-93-6P 612494-94-7P
612494-95-8P 612494-96-9P 612494-97-0P 612494-98-1P 612494-99-2P
612495-00-8P 612495-01-9P 612495-02-0P 612495-03-1P 612495-04-2P
612495-05-3P 612495-06-4P 612495-07-5P 612495-08-6P 612495-09-7P
612495-10-0P 612495-11-1P 612495-12-2P 612495-13-3P 612495-14-4P
612495-15-5P 612495-18-8P 612495-19-9P 612495-20-2P 612495-21-3P
612495-22-4P, N-(2-Chlorophenyl)-N'-[3-[3-[(2-chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]urea hydrochloride 612495-24-6P 612495-25-7P 612495-26-8P 612495-27-9P
612495-28-0P, N'-(2-Chlorophenyl)-N-[3-[3-[(2-chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-methylurea hydrochloride 612495-29-1P 612495-30-4P,
N-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N'-(3,5-dimethoxyphenyl)-N-methylurea hydrochloride 612495-31-5P 612495-32-6P 612495-33-7P 612495-34-8P
612495-35-9P 612495-36-0P 612495-37-1P 612495-38-2P 612495-39-3P
612495-40-6P 612495-41-7P 612495-42-8P 612495-43-9P 612495-44-0P
612495-45-1P 612495-47-3P 612495-48-4P 612495-49-5P 612495-50-8P
612495-51-9P 612495-52-0P 612495-53-1P 612495-54-2P 612495-55-3P
612495-56-4P 612495-57-5P 612495-58-6P 612495-59-7P 612495-60-0P
612495-61-1P 612495-62-2P 612495-63-3P 612495-64-4P 612495-66-6P
612495-67-7P 612495-68-8P 612495-69-9P 612495-70-2P 612495-71-3P
612495-72-4P 612495-73-5P 612495-74-6P 612495-75-7P 612495-76-8P
612495-77-9P 612495-78-0P 612495-79-1P 612495-80-4P 612495-81-5P
612495-82-6P 612495-83-7P 612495-84-8P 612495-85-9P 612495-86-0P
612495-87-1P 612495-88-2P 612495-89-3P 612495-90-6P 612495-91-7P
612495-92-8P 612495-93-9P 612495-94-0P 612495-95-1P 612495-96-2P
612495-97-3P 612495-98-4P 612495-99-5P 612496-00-1P 612496-01-2P
612496-02-3P 612496-03-4P 612496-04-5P 612496-06-7P 612496-07-8P
612496-08-9P 612496-09-0P 612496-10-3P 612496-12-5P 612496-13-6P
612496-14-7P 612496-15-8P 612496-16-9P 612496-17-0P 612496-18-1P
612496-19-2P 612496-20-5P 612496-21-6P 612496-22-7P 612496-23-8P
612496-24-9P 612496-25-0P 612496-26-1P 612496-27-2P 612496-28-3P
612496-29-4P 612496-30-7P 612496-31-8P 612496-32-9P 612496-33-0P
612496-34-1P 612496-35-2P 612496-36-3P 612496-37-4P 612496-38-5P
612496-39-6P 612496-40-9P 612496-42-1P 612496-43-2P 612496-44-3P
612496-45-4P 612496-46-5P 612496-47-6P 612496-48-7P 612496-49-8P
612496-50-1P 612496-51-2P 612496-52-3P 612496-53-4P 612496-54-5P
612496-55-6P 612496-56-7P 612496-57-8P 612496-58-9P 612496-59-0P
612496-60-3P 612496-61-4P 612496-62-5P 612496-63-6P 612496-64-7P

612496-65-8P 612496-66-9P 612496-67-0P 612496-68-1P 612496-69-2P
612496-70-5P 612496-71-6P 612496-72-7P 612496-73-8P 612496-74-9P
612496-75-0P 612496-76-1P 612496-77-2P 612496-78-3P 612496-79-4P
612496-80-7P 612496-81-8P 612496-82-9P 612496-83-0P 612496-84-1P
612496-85-2P 612496-86-3P 612496-87-4P 612496-88-5P 612496-89-6P
612496-90-9P 612496-91-0P 612496-92-1P 612496-93-2P 612496-94-3P
612496-95-4P 612496-96-5P 612496-97-6P 612496-98-7P 612496-99-8P
612497-00-4P 612497-01-5P 612497-02-6P 612497-03-7P 612497-04-8P
612497-05-9P 612497-06-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

IT 612497-07-1P 612497-08-2P 612497-09-3P 612497-10-6P 612497-11-7P
612497-12-8P 612497-13-9P 612497-14-0P 612497-15-1P,
N-(2-Chlorophenyl)-N'-[3-[3-[(2-chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]urea 612497-16-2P 612497-17-3P
612497-18-4P 612497-19-5P, N-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-methylbenzenesulfonamide 612497-20-8P, N'-(2-Chlorophenyl)-N-[3-[3-[(2-chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-methylurea 612497-21-9P 612497-22-0P, N-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N'-(3,5-dimethoxyphenyl)-N-methylurea 612497-23-1P 612497-24-2P 612497-25-3P
612497-26-4P 612497-27-5P 612497-28-6P 612497-29-7P 612497-30-0P
612497-31-1P 612497-32-2P 612497-33-3P 612497-34-4P 612497-35-5P
612497-36-6P 612497-37-7P 612497-38-8P 612497-39-9P 612497-40-2P
612497-41-3P 612497-42-4P 612497-43-5P 612497-44-6P 612497-45-7P
612497-46-8P 612497-47-9P 612497-48-0P 612497-49-1P 612497-50-4P
612497-51-5P 612497-52-6P 612497-53-7P 612497-54-8P 612497-55-9P
612497-56-0P 612497-57-1P 612497-58-2P 612497-59-3P 612497-60-6P
612497-61-7P 612497-62-8P 612497-63-9P 612497-64-0P 612497-65-1P
612497-66-2P 612497-67-3P 612497-68-4P 612497-69-5P 612497-70-8P
612497-71-9P 612497-72-0P 612497-73-1P 612497-74-2P 612497-75-3P
612497-76-4P 612497-77-5P 612497-78-6P 612497-79-7P 612497-80-0P
612497-81-1P 612497-82-2P 612497-83-3P 612497-84-4P 612497-85-5P
612497-86-6P 612497-87-7P 612497-88-8P 612497-89-9P 612497-90-2P
612497-91-3P 612497-92-4P 612497-93-5P 612497-94-6P 612497-95-7P
612497-96-8P 612497-97-9P, N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)[3-[3-(2-methyl-2-aminopropyl)phenoxy]propyl]amine
612497-98-0P 612497-99-1P 612498-00-7P 612498-01-8P 612498-02-9P
612498-03-0P 612498-04-1P 612498-05-2P 612498-06-3P 612498-07-4P
612498-08-5P 612498-09-6P 612498-10-9P 612498-11-0P 612498-12-1P
612498-13-2P 612498-14-3P 612498-15-4P 612498-16-5P 612498-17-6P
612498-18-7P 612498-20-1P 612498-21-2P 612498-22-3P 612498-23-4P,
2-(2-Chloro-3-trifluoromethylbenzylamino)-1-phenylethanol 612498-24-5P
612498-46-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

IT 79-03-8, Propanoyl chloride 95-92-1, Diethyl oxalate 513-36-0, Isobutyl chloride 13831-31-7, Acetoxyacetyl chloride 55458-67-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or

treatment of LXR-mediated diseases)

IT 50-00-0, Formaldehyde, reactions 64-04-0, Phenethylamine 64-19-7, Acetic acid, reactions 65-85-0, Benzoic acid, reactions 67-64-1, Acetone, reactions 74-88-4, Methyl iodide, reactions 74-89-5, Methylamine, reactions 75-03-6, Iodoethane 75-04-7, Ethylamine, reactions 75-07-0, Acetaldehyde, reactions 75-25-2, Bromoform 75-31-0, Isopropylamine, reactions 75-36-5, Acetyl chloride 75-90-1, 2,2,2-Trifluoroacetaldehyde 78-81-9, Isobutylamine 78-84-2, Isobutyraldehyde 79-31-2, Isobutyric acid 83-13-6, Diethyl phenylmalonate 88-15-3, 2-Acetylthiophene 90-05-1, 2-Methoxyphenol 91-68-9, 3-Diethylaminophenol 93-25-4, o-Methoxyphenylacetic acid 95-48-7, o-Cresol, reactions 95-57-8, 2-Chlorophenol 96-17-3, 2-Methylbutyraldehyde 96-32-2, Methyl bromoacetate 97-96-1, 2-Ethylbutyraldehyde 98-09-9, Benzenesulfonyl chloride 98-17-9, 3-Trifluoromethylphenol 98-59-9, p-Toluenesulfonyl chloride 100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 100-83-4, 3-Hydroxybenzaldehyde 101-18-8, 3-Phenylaminophenol 104-01-8, p-Methoxyphenylacetic acid 107-10-8, n-Propylamine, reactions 108-39-4, m-Cresol, reactions 108-43-0, 3-Chlorophenol 108-46-3, 3-Hydroxyphenol, reactions 108-95-2, Phenol, reactions 109-01-3, 1-Methylpiperazine 109-64-8, 1,3-Dibromopropane 109-73-9, 1-Butylamine, reactions 110-52-1, 1,4-Dibromobutane 110-62-3, Valeraldehyde 110-91-8, Morpholine, reactions 118-31-0, 1-Naphthalenemethylamine 120-57-0, Benzo[1,3]dioxole-5-carboxaldehyde 120-80-9, 2-Hydroxyphenol, reactions 120-92-3, Cyclopentanone 121-51-7, 3-Nitrobenzenesulfonyl chloride 121-71-1 122-03-2, 4-Isopropylbenzaldehyde 123-08-0, 4-Hydroxybenzaldehyde 123-72-8, Butyraldehyde 123-75-1, Pyrrolidine, reactions 123-90-0, Thiomorpholine 124-40-3, Dimethylamine, reactions 124-63-0, Methanesulfonyl chloride 147-85-3, (S)-Pyrrolidine-2-carboxylic acid, reactions 150-19-6, 3-Methoxyphenol 150-76-5, 4-Methoxyphenol 344-25-2, (R)-Pyrrolidine-2-carboxylic acid 421-83-0, Trifluoromethanesulfonyl chloride 504-02-9, Cyclohexane-1,3-dione 527-69-5, Furan-2-carbonyl chloride 533-31-3, Sesamol 536-90-3, 3-Methoxyphenylamine 554-84-7, 3-Nitrophenol 590-86-3, Isovaleraldehyde 591-20-8, 3-Bromophenol 591-27-5, 3-Aminophenol 594-44-5, Ethanesulfonyl chloride 610-78-6, 4-Chloro-3-nitrophenol 611-20-1, 2-Cyanophenol 616-34-2, Glycine methyl ester 618-45-1, 3-Isopropylphenol 621-37-4 624-84-0, Formic hydrazide 627-18-9 627-30-5, 3-Chloro-1-propanol 627-31-6 628-21-7, 1,4-Diiodobutane 680-15-9, Methyl fluorosulfonyl difluoroacetate 873-62-1, 3-Cyanophenol 927-74-2, 1-Hydroxybut-3-yne 939-97-9, 4-tert-Butylbenzaldehyde 1122-62-9, 1-Pyridin-2-ylethanone 1458-98-6, 2-Methylallyl bromide 1489-69-6, Cyclopropylcarboxaldehyde 1648-99-3, 2,2,2-Trifluoroethanesulfonyl chloride 1722-12-9, 2-Chloropyrimidine 1878-65-5, m-Chlorophenylacetic acid 1878-66-6, p-Chlorophenylacetic acid 2444-36-2, o-Chlorophenylacetic acid 3188-13-4, Chloromethyl ethyl ether 3320-83-0, 2-Chlorophenyl isocyanate 3446-89-7, 4-Methylsulfanylbenzaldehyde 3894-09-5, 2-Cyclohexyl-2-phenylacetic acid 3963-62-0, 2,2-Diphenethylamine 4009-98-7, Methoxymethyltriphenylphosphonium chloride 4023-34-1, Cyclopropanecarbonyl chloride 4074-43-5, 3-Butylphenol 4187-38-6 4648-54-8, Trimethylsilyl azide 5458-84-4, 2-Iodo-5-nitroanisole 5460-31-1, 2-Methyl-3-nitrophenol 5473-12-1, (Methylamino)acetic acid methyl ester 6456-74-2 6622-91-9, 4-Pyridylacetic acid hydrochloride 7497-87-2 7568-93-6, 2-Amino-1-phenylethanol 10065-72-2 10130-74-2, 3-Methoxybenzenesulfonyl chloride 10147-36-1, Propane-1-sulfonyl chloride 10147-37-2, Isopropylsulfonyl chloride 13257-67-5, 2-Amino-2-methylpropionic acid methyl ester 16879-02-0, 6-Chloro-2-pyridinol 17596-79-1, (S)-(-)-2-Phenylpropylamine 18162-48-6, tert-

Butyldimethylsilyl chloride 19438-10-9, Methyl 3-hydroxybenzoate 20967-96-8, 3-Benzyloxyphenylacetonitrile 21404-88-6 22868-60-6 24033-03-2, 3-Benzyloxybenzyl chloride 24424-99-5, Di-tert-butyl dicarbonate 25054-53-9, Piperonyloyl chloride 26628-22-8, Sodium azide 27292-49-5, 3-Morpholin-4-ylphenol 27292-50-8, 3-Piperidin-1-ylphenol 27298-98-2 27757-85-3, (Thiophen-2-ylmethyl)amine 28163-64-6, (R)-2-Phenylpropylamine 29668-44-8 30749-25-8, 3-Isobutylphenol 31466-44-1 31788-88-2 34577-88-3, 2-Phenylbutylamine 39226-96-5, 2-Chloro-3-trifluoromethylbenzylamine 41003-94-5, Diethylisocyanomethyl phosphonate 50868-72-9 51558-14-6, 2-(4-Methoxyphenyl)propylamine 53332-80-2, [(1H-Imidazol-2-yl)methyl]amine 54132-76-2, 3,5-Dimethoxyphenyl isocyanate 55163-76-3, (R)-β-Methoxyphenethylamine 58971-10-1 59576-26-0 59817-32-2 73604-31-6, 3-Hydroxybenzylamine 75351-36-9 78659-23-1, 2-Trifluoromethyl-2-phenylacetaldehyde 79558-08-0, 3-Hydroxyphenoxyacetic acid methyl ester 82614-88-8 93118-03-7, 2-Chloro-3-trifluoromethylbenzaldehyde 97608-33-8 98244-48-5, (S)-(+)-3-Bromo-2-methyl-1-propanol 101144-99-4 108122-24-3 124312-73-8, (1-Methyl-1H-imidazol-2-yl)methylamine 135427-08-6, 4-Fluoro-3-methylbenzaldehyde 165047-24-5, 2,4,5-Trifluorobenzaldehyde 174472-00-5, (S)-β-Methoxyphenethylamine 196106-01-1 224450-48-0 258348-24-2 345893-26-7 405911-09-3 502649-73-2 610318-50-8 610318-54-2 612498-38-1, 3-(3-Benzyloxybenzyl)-3H-1,2,3,4-tetrazole 612498-61-0 612498-78-9 612498-81-4 612498-85-8, 2-Trifluoromethyl-5-nitrophenol 612498-92-7 612498-94-9 612499-04-4, (5-Bromothiophen-2-ylmethyl)amine **612499-11-3 612499-12-4** 612499-24-8 612499-53-3 612499-54-4 612499-63-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

IT **612498-89-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

RN 612498-89-2 HCAPLUS

CN Morpholine, 4-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:796421 HCAPLUS

DN 139:302072

ED Entered STN: 10 Oct 2003
TI Methods of treatment with LXR modulators
IN Cairns, William J.; Irving, Elaine A.; Parsons, Andrew A.; Soden, Peter E.; Richardson, Jill C.; Burbidge, Stephen A.; Vinson, Mary; Watson, Mike A.; Whitney, Karl
PA **Smithkline Beecham Corporation, USA**
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 1-12 (Pharmacology)
Section cross-reference(s): 25, 27, 28
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003082198	A2	20031009	WO 2003-US9225	20030326
	WO 2003082198	A3	20041223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	EP 1511483	A2	20050309	EP 2003-716832	20030326

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRAI	US 2002-368424P	P	20020327
	WO 2003-US9225	W	20030326

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003082198	ICM	A61K
WO 2003082198	ECLA	A61K031/00; A61K031/222; A61K031/423

OS MARPAT 139:302072
AB In one aspect, the present invention provides the use of an LXR receptor agonist in the manufacture of medicaments for the treatment and/or prevention of diseases or conditions characterized by neuron degeneration, inflammation in the CNS, injury or impaired plasticity. In another aspect, the present invention provides a method for treating a patient suffering from a disease selected from the group consisting of: stroke, Alzheimer's disease, fronto-temporal dementias, peripheral neuropathy, Parkinson's disease, dementia with Lewy bodies, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis, said method comprising the step of administering to said patient an effective amount of an LXR receptor modulator in combination with a carrier. In yet another aspect, the present invention provides a method for promoting cholesterol efflux in at least one astroglial cell, said method comprising the step of: contacting said at least one astroglial cell with a cholesterol-efflux-promoting effective amount of an LXR receptor modulator in combination with a carrier.
ST LXR receptor modulator nervous system disease treatment
IT Nervous system, disease
(Huntington's chorea; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT Steroid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LXR (liver X receptor); methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LXR receptor-encoding; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Nervous system, disease
(amyotrophic lateral sclerosis; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Drug delivery systems
(carriers; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Inflammation
Injury
(central nervous system; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Nervous system, disease
(central, inflammation; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Nervous system, disease
(central, injury; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Nerve, disease
(degeneration; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Mental disorder
(dementia, fronto-temporal dementia; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Mental disorder
(depression; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Mental disorder
(diffuse Lewy body disease; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Injury
(head; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Synaptic plasticity
(impaired; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)
IT Head, disease
Spinal cord, disease
(injury; methods of treatment of neuron degeneration and inflammation

in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT Alzheimer's disease
Anti-Alzheimer's agents
Anti-inflammatory agents
Antidepressants
Antiparkinsonian agents
Antipsychotics
Astrocyte
Mental disorder
Multiple sclerosis
Parkinson's disease
Schizophrenia
(methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT Nerve, disease
(peripheral neuropathy; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT Axon
(promotion of outgrowth of; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT Injury
(spinal cord; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT Brain, disease
(stroke; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT Head, disease
Spinal cord, disease
(trauma; methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT 293754-55-9P 405911-09-3P 609772-04-5P 609772-06-7P
609772-12-5P 609772-17-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT 194608-77-0 344327-48-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT 98-09-9, Benzenesulfonyl chloride 98-59-9, p-Toluenesulfonyl chloride 407-25-0, Trifluoroacetic anhydride 621-37-4, (3-Hydroxyphenyl)acetic acid 627-18-9, 3-Bromo-1-propanol 722-92-9, 4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]aniline 927-74-2, 3-Butyn-1-ol

3188-13-4, Chloromethyl ethyl ether 3963-62-0 4648-54-8, Trimethylsilyl azide 6308-98-1, Diphenethylamine 17596-79-1, (S)-2-Phenylpropylamine 20967-96-8, 3-Benzyloxyphenylacetonitrile 24621-61-2, (S)-1,3-Butanediol 42058-59-3, (3-Hydroxyphenyl)acetic acid methyl ester 93118-03-7, 2-Chloro-3-trifluoromethylbenzaldehyde 114774-44-6 228579-12-2 405911-35-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT 70430-20-5P 82614-88-8P 609772-03-4P 609772-05-6P 609772-07-8P 609772-08-9P 609772-09-0P 609772-10-3P 609772-11-4P 609772-13-6P 609772-14-7P 609772-15-8P 609772-16-9P 609772-18-1P 609772-19-2P 609772-20-5P 609772-21-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

IT 611275-42-4, 1: PN: WO03082198 SEQID: 1 unclaimed DNA 611275-44-6, 3: PN: WO03082198 SEQID: 3 unclaimed DNA 611275-46-8 611275-47-9
RL: PRP (Properties)
(unclaimed nucleotide sequence; methods of treatment with LXR modulators)

IT 611275-43-5 611275-45-7
RL: PRP (Properties)
(unclaimed protein sequence; methods of treatment with LXR modulators)

IT 611275-48-0 611275-49-1 611275-50-4
RL: PRP (Properties)
(unclaimed sequence; methods of treatment with LXR modulators)

IT **609772-12-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

RN 609772-12-5 HCAPLUS
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> => fil reg
FILE 'REGISTRY' ENTERED AT 13:32:59 ON 09 JUN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JUN 2005 HIGHEST RN 851931-88-9
DICTIONARY FILE UPDATES: 8 JUN 2005 HIGHEST RN 851931-88-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d his l27-

(FILE 'USPATFULL, USPAT2' ENTERED AT 13:29:51 ON 09 JUN 2005)

FILE 'USPATFULL, USPAT2' ENTERED AT 13:30:15 ON 09 JUN 2005

FILE 'HCAPLUS' ENTERED AT 13:31:29 ON 09 JUN 2005
SEL HIT RN L25 2 3

FILE 'REGISTRY' ENTERED AT 13:32:38 ON 09 JUN 2005
L27 15 S E1-E15

FILE 'REGISTRY' ENTERED AT 13:32:59 ON 09 JUN 2005

=> d ide can tot l27

L27 ANSWER 1 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612499-12-4** REGISTRY
ED Entered STN: 04 Nov 2003
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N-methylacetamide
FS 3D CONCORD
MF C34 H34 Cl F3 N2 O2
CI COM

SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 2 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612499-11-3** REGISTRY
ED Entered STN: 04 Nov 2003
CN Piperazine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-(4-methylpiperazin-1-yl)ethanone
FS 3D CONCORD
MF C38 H41 Cl F3 N3 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 3 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612499-10-2** REGISTRY
ED Entered STN: 04 Nov 2003
CN Morpholine, 4-[[3-[(3R)-3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,

2-diphenylethyl)amino]butoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (R)-2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]butoxy]phenyl]-1-morpholin-4-ylethanone hydrochloride
FS STEREOSEARCH
MF C38 H40 Cl F3 N2 O3 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (691894-10-7)

Absolute stereochemistry.



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 4 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612499-09-9** REGISTRY
ED Entered STN: 04 Nov 2003
CN Morpholine, 4-[[3-[(2R)-3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]-2-methylpropoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (R)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methylpropoxy]phenyl]-1-morpholin-4-ylethanone hydrochloride
FS STEREOSEARCH
MF C38 H40 Cl F3 N2 O3 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (691894-09-4)

Absolute stereochemistry.



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 5 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612499-08-8** REGISTRY
ED Entered STN: 04 Nov 2003
CN Pyrrolidine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-pyrrolidin-1-ylethanone hydrochloride
MF C37 H38 Cl F3 N2 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (691893-68-2)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 6 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612499-07-7** REGISTRY
ED Entered STN: 04 Nov 2003
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N,N-dimethylacetamide hydrochloride
MF C35 H36 Cl F3 N2 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (691893-66-0)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 7 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612499-06-6** REGISTRY
ED Entered STN: 04 Nov 2003
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N-ethylacetamide hydrochloride
MF C35 H36 Cl F3 N2 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (691893-69-3)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 8 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612499-05-5** REGISTRY
ED Entered STN: 04 Nov 2003
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-thienylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(thiophen-2-yl)methyl]acetamide hydrochloride
MF C38 H36 Cl F3 N2 O2 S . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (691893-74-0)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 9 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612499-03-3** REGISTRY
ED Entered STN: 04 Nov 2003
CN Benzeneacetamide, N-[(5-bromo-2-thienyl)methyl]-3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N-[(5-Bromothiophen-2-yl)methyl]-2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]acetamide hydrochloride
MF C38 H35 Br Cl F3 N2 O2 S . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (691893-73-9)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 10 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612499-02-2** REGISTRY
ED Entered STN: 04 Nov 2003
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(1H-imidazol-2-ylmethyl)-,

monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-[(1H-imidazol-2-yl)methyl]acetamide hydrochloride
MF C37 H36 Cl F3 N4 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (690955-08-9)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 11 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612499-01-1** REGISTRY
ED Entered STN: 04 Nov 2003
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-N-methylacetamide hydrochloride
MF C34 H34 Cl F3 N2 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (612499-12-4)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 12 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612499-00-0** REGISTRY
ED Entered STN: 04 Nov 2003
CN Piperazine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-(4-methylpiperazin-1-yl)ethanone hydrochloride
MF C38 H41 Cl F3 N3 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (612499-11-3)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 13 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612498-99-4** REGISTRY
ED Entered STN: 04 Nov 2003
CN Morpholine, 4-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]-1-morpholin-4-ylethanone hydrochloride
MF C37 H38 Cl F3 N2 O3 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (691893-65-9)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 14 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612498-89-2** REGISTRY
ED Entered STN: 04 Nov 2003
CN Morpholine, 4-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)((S)-2-phenylpropyl)amino]propoxy]phenyl]-1-morpholin-4-ylethanone
FS STEREOSEARCH
MF C32 H36 Cl F3 N2 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:323535

L27 ANSWER 15 OF 15 REGISTRY COPYRIGHT 2005 ACS on STN

RN **609772-12-5** REGISTRY
ED Entered STN: 28 Oct 2003
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H30 Cl F3 N2 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:6921

REFERENCE 2: 139:302072

=> => s l20 not l27
L28 98 L20 NOT L27

=> d scan

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Morpholine, 4-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]benzoyl]- (9CI)
MF **C36 H36 Cl F3 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):97

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-(9CI)
MF **C37 H36 Cl F3 N4 O3**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-, monohydrochloride (9CI)
MF **C37 H36 Cl F3 N4 O3 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N,N-diethyl- (9CI)
MF **C37 H40 Cl F3 N2 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(1H-imidazol-2-ylmethyl)- (9CI)
MF **C37 H36 Cl F3 N4 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-phenyl- (9CI)
MF **C38 H34 Cl F3 N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(3-methoxypropyl)- (9CI)
MF **C37 H40 Cl F3 N2 O3**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(3-methoxypropyl)-, monohydrochloride (9CI)
MF **C37 H40 Cl F3 N2 O3 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-ethyl- (9CI)
MF **C35 H36 Cl F3 N2 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]-N-methyl- (9CI)
MF **C29 H32 Cl F3 N2 O2**
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N,N-dimethyl- (9CI)
MF **C34 H34 Cl F3 N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[3-(1-methylethoxy)propyl]- (9CI)
MF **C39 H44 Cl F3 N2 O3**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[3-(1-methylethoxy)propyl]-, monohydrochloride (9CI)
MF **C39 H44 Cl F3 N2 O3 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrrolidine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]- (9CI)
MF **C37 H38 Cl F3 N2 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]- (9CI)
MF **C28 H30 Cl F3 N2 O2**
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-[4-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]benzoyl]-4-methyl- (9CI)
MF **C37 H39 Cl F3 N3 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-phenoxyethyl)- (9CI)
MF **C41 H40 Cl F3 N2 O3**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-phenoxyethyl)-, monohydrochloride (9CI)

MF **C41 H40 Cl F3 N2 O3 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]- (9CI)
MF **C38 H40 Cl F3 N2 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]-N-ethyl- (9CI)
MF **C30 H34 Cl F3 N2 O2**
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Morpholine, 4-[4-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]benzoyl]- (9CI)
MF **C36 H36 Cl F3 N2 O3**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[2-(2-pyridinyl)ethyl]- (9CI)
MF **C40 H39 Cl F3 N3 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[2-(2-pyridinyl)ethyl]-, monohydrochloride (9CI)
MF **C40 H39 Cl F3 N3 O2 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N,N-dimethyl- (9CI)
MF **C35 H36 Cl F3 N2 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Morpholine, 4-[[3-[(3R)-3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]butoxy]phenyl]acetyl]- (9CI)
MF **C38 H40 Cl F3 N2 O3**
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, 4-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N,N-dimethyl- (9CI)
MF **C34 H34 Cl F3 N2 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(3-pyridinylmethyl)- (9CI)
MF **C39 H37 Cl F3 N3 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(3-pyridinylmethyl)-, monohydrochloride (9CI)
MF **C39 H37 Cl F3 N3 O2 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Morpholine, 4-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]- (9CI)
MF **C37 H38 Cl F3 N2 O3**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Morpholine, 4-[[3-[(2R)-3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]-2-methylpropoxy]phenyl]acetyl]- (9CI)
MF **C38 H40 Cl F3 N2 O3**
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Glycine, N-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-, monohydrochloride (9CI)
MF **C35 H34 Cl F3 N2 O4 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
MF **C39 H43 Cl F3 N3 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI)
MF **C39 H43 Cl F3 N3 O2 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]-N,N-dimethyl-, monohydrochloride (9CI)
MF **C30 H34 Cl F3 N2 O2 . Cl H**

Absolute stereochemistry.



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Glycine, N-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]- (9CI)
MF **C35 H34 Cl F3 N2 O4**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN β-Alanine, N-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-, 1,1-dimethylethyl ester (9CI)
MF **C40 H44 Cl F3 N2 O4**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[2-(4-thiomorpholinyl)ethyl]- (9CI)
MF **C39 H43 Cl F3 N3 O2 S**
CI COM

PAGE 1-A



PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[2-(4-thiomorpholinyl)ethyl]-, monohydrochloride (9CI)
MF **C39 H43 Cl F3 N3 O2 S . Cl H**

PAGE 1-A



● HCl

PAGE 1-B

—CF_3

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]-N-methyl-, monohydrochloride (9CI)
MF **C29 H32 Cl F3 N2 O2 . Cl H**

Absolute stereochemistry.



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN β-Alanine, N-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]- (9CI)
MF **C36 H36 Cl F3 N2 O4**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN β-Alanine, N-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-, monohydrochloride (9CI)
MF **C36 H36 Cl F3 N2 O4 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[(3-methyl-5-isoxazolyl)methyl]- (9CI)
MF **C38 H37 Cl F3 N3 O3**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[(3-methyl-5-isoxazolyl)methyl]-, monohydrochloride (9CI)
MF **C38 H37 Cl F3 N3 O3 . Cl H**



L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]-, monohydrochloride (9CI)
MF **C28 H30 Cl F3 N2 O2 . Cl H**

Absolute stereochemistry.



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Thiopheneacetic acid, α-[[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]amino]- (9CI)
MF **C39 H36 Cl F3 N2 O4 S**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Thiopheneacetic acid, α-[[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]amino]-, monohydrochloride (9CI)
MF **C39 H36 Cl F3 N2 O4 S . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-furanylmethyl)- (9CI)
MF **C38 H36 Cl F3 N2 O3**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-furanylmethyl)-, monohydrochloride (9CI)
MF **C38 H36 Cl F3 N2 O3 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]-N,N-dimethyl- (9CI)
MF **C30 H34 Cl F3 N2 O2**
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[2-(2-hydroxyethoxy)ethyl]- (9CI)
MF **C37 H40 Cl F3 N2 O4**
CI COM

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[2-(2-hydroxyethoxy)ethyl]-, monohydrochloride (9CI)
MF **C37 H40 Cl F3 N2 O4 . Cl H**

PAGE 1-A



● HCl

PAGE 1-B



L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N,N-bis(2-methoxyethyl)- (9CI)
MF **C39 H44 Cl F3 N2 O4**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N,N-bis(2-methoxyethyl)-, monohydrochloride (9CI)
MF **C39 H44 Cl F3 N2 O4 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]-N-ethyl-, monohydrochloride (9CI)
MF **C30 H34 Cl F3 N2 O2 . Cl H**

Absolute stereochemistry.



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-decyl- (9CI)
MF **C43 H52 Cl F3 N2 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-decyl-, monohydrochloride (9CI)
MF **C43 H52 Cl F3 N2 O2 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-methoxyethyl)-N-methyl- (9CI)

MF **C37 H40 Cl F3 N2 O3**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-methoxyethyl)-N-methyl-, monohydrochloride (9CI)
MF **C37 H40 Cl F3 N2 O3 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Morpholine, 4-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]phenyl]acetyl]-, monohydrochloride (9CI)
MF **C32 H36 Cl F3 N2 O3 . Cl H**

Absolute stereochemistry.



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-octyl- (9CI)
MF **C41 H48 Cl F3 N2 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-octyl-, monohydrochloride (9CI)
MF **C41 H48 Cl F3 N2 O2 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-methoxy-1-methylethyl)- (9CI)
MF **C37 H40 Cl F3 N2 O3**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-methoxy-1-methylethyl)-, monohydrochloride (9CI)
MF **C37 H40 Cl F3 N2 O3 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-methyl-N-(methylsulfonyl)- (9CI)
MF **C35 H36 Cl F3 N2 O4 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI)
MF **C40 H45 Cl F3 N3 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[(1-ethyl-2-pyrrolidinyl)methyl]-, monohydrochloride (9CI)
MF **C40 H45 Cl F3 N3 O2 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[2-(4-morpholinyl)ethyl]- (9CI)
MF **C39 H43 Cl F3 N3 O3**
CI COM

PAGE 1-A



PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI)
MF **C39 H43 Cl F3 N3 O3 . Cl H**

PAGE 1-A



● HCl

PAGE 1-B

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-methyl-N-(phenylsulfonyl)- (9CI)
MF **C40 H38 Cl F3 N2 O4 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[(tetrahydro-2-furanyl)methyl]- (9CI)
MF **C38 H40 Cl F3 N2 O3**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[(tetrahydro-2-furanyl)methyl]-, monohydrochloride (9CI)
MF **C38 H40 Cl F3 N2 O3 . Cl H**



L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[2-(dimethylamino)ethyl]- (9CI)
MF **C37 H41 Cl F3 N3 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI)
MF **C37 H41 Cl F3 N3 O2 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(phenylsulfonyl)- (9CI)
MF **C39 H36 Cl F3 N2 O4 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-pyridinylmethyl)- (9CI)
MF **C39 H37 Cl F3 N3 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-pyridinylmethyl)-, monohydrochloride (9CI)
MF **C39 H37 Cl F3 N3 O2 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-methoxyethyl)- (9CI)
MF **C36 H38 Cl F3 N2 O3**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-methoxyethyl)-, monohydrochloride (9CI)
MF **C36 H38 Cl F3 N2 O3 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(methylsulfonyl)- (9CI)
MF **C34 H34 Cl F3 N2 O4 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[(5-methyl-1H-1,2,4-triazol-3-yl)methyl]-(9CI)
MF **C37 H37 Cl F3 N5 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[(5-methyl-1H-1,2,4-triazol-3-yl)methyl]-, monohydrochloride (9CI)
MF **C37 H37 Cl F3 N5 O2 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-thienylmethyl)- (9CI)
MF **C38 H36 Cl F3 N2 O2 S**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Azepine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]hexahydro-, monohydrochloride (9CI)
MF **C39 H42 Cl F3 N2 O2 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(phenylsulfonyl)- (9CI)
MF **C38 H34 Cl F3 N2 O4 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(3-thienylmethyl)- (9CI)
MF **C38 H36 Cl F3 N2 O2 S**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(3-thienylmethyl)-, monohydrochloride (9CI)
MF **C38 H36 Cl F3 N2 O2 S . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, N-[(5-bromo-2-thienyl)methyl]-3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI)
MF **C38 H35 Br Cl F3 N2 O2 S**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Azetidine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-, monohydrochloride (9CI)
MF **C36 H36 Cl F3 N2 O2 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(methylsulfonyl)- (9CI)
MF **C33 H32 Cl F3 N2 O4 S**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[1-(2-thienyl)ethyl]- (9CI)
MF **C39 H38 Cl F3 N2 O2 S**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[1-(2-thienyl)ethyl]-, monohydrochloride (9CI)
MF **C39 H38 Cl F3 N2 O2 S . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Azepine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]hexahydro- (9CI)
MF **C39 H42 Cl F3 N2 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N,N-diethyl-, monohydrochloride (9CI)
MF **C37 H40 Cl F3 N2 O2 . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]benzoyl]-4-methyl- (9CI)
MF **C37 H39 Cl F3 N3 O2**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[(4-methyl-2-thiazolyl)methyl]- (9CI)
MF **C38 H37 Cl F3 N3 O2 S**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-[(4-methyl-2-thiazolyl)methyl]-, monohydrochloride (9CI)
MF **C38 H37 Cl F3 N3 O2 S . Cl H**



● HCl

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Azetidine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]- (9CI)
MF **C36 H36 Cl F3 N2 O2**
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L28 98 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-, monohydrochloride (9CI)
MF **C38 H40 Cl F3 N2 O2 . Cl H**



● HCl

ALL ANSWERS HAVE BEEN SCANNED

=> => d his l29-

(FILE 'REGISTRY' ENTERED AT 13:32:59 ON 09 JUN 2005)

FILE 'HCAPLUS' ENTERED AT 13:36:40 ON 09 JUN 2005
L29 710 S LXR
L30 603 S LIVER X RECEPTOR
L31 611 S RECEPTOR (L) LIVER X
L32 769 S L29-L31

FILE 'REGISTRY' ENTERED AT 13:37:47 ON 09 JUN 2005

FILE 'HCAPLUS' ENTERED AT 13:37:58 ON 09 JUN 2005
L33 766 S L32 NOT L25

FILE 'REGISTRY' ENTERED AT 13:38:05 ON 09 JUN 2005

FILE 'HCAPLUS' ENTERED AT 13:38:05 ON 09 JUN 2005
SET SMARTSELECT ON
L34 SEL L33 1- RN : 11740 TERMS
SET SMARTSELECT OFF

FILE 'REGISTRY' ENTERED AT 13:38:27 ON 09 JUN 2005
L35 11740 S L34
L36 9 S L14 SAM SUB=L35
L37 280 S L14 FUL SUB=L35

```
SAV L37 KUMAR508A/A

     FILE 'HCAPLUS' ENTERED AT 13:59:18 ON 09 JUN 2005
L38            5 S L37
L39            5 S L38 AND L1-L11,L29-L32
L40            5 S L38 AND (GLAXO? OR SMITH? OR KLINE? OR BEECHAM?)/PA,CS
L41            5 S L39,L40

=> fil reg
FILE 'REGISTRY' ENTERED AT 14:07:39 ON 09 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     8 JUN 2005  HIGHEST RN 851931-88-9
DICTIONARY FILE UPDATES:    8 JUN 2005  HIGHEST RN 851931-88-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d l14
L14 HAS NO ANSWERS
L14             STR
```



REP G1=(0-8) C
VAR G2=O/S/N/C
REP G3=(2-8) C
REP G4=(0-1) C
VAR G5=C/CY
NODE ATTRIBUTES:
NSPEC IS RC AT 1
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 14:07:48 ON 09 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 9 Jun 2005 VOL 142 ISS 24
FILE LAST UPDATED: 8 Jun 2005 (20050608/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d all fhitstr tot l41

L41 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:232611 HCAPLUS
DN 142:297990
ED Entered STN: 17 Mar 2005
TI Preparation of 5-membered heterocyclic derivatives as modulators of **liver X receptors**
IN Hoang, Tram H.; **Thompson, Scott K.**; Washburn, David G.
PA **Smithkline Beecham Corporation, USA**
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-415
ICS A61K031-42; A61K031-5377; A61K031-541; C07D231-20; C07D261-12; C07D413-02; C07D417-02
CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005023247	A1	20050317	WO 2004-US28629	20040902

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-499762P P 20030903

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005023247	ICM	A61K031-415
	ICS	A61K031-42; A61K031-5377; A61K031-541; C07D231-20; C07D261-12; C07D413-02; C07D417-02

OS MARPAT 142:297990

GI



I



II

AB Title compds. I [A = 5 membered heterocyclic group comprising of 1, 2, or 3 heteroatoms independently selected from N, O, or S, wherein N or S is

optionally oxidized; B = -(O)x; Y = -O-, -S-, -N(R8)-, etc.; W1 = (un)substituted-cycloalkyl, -aryl, -heterocycle; W2 = H, halo, alkynyl, etc.; W3 = H, halo, (un)substituted alkyl, etc.; Q = (un)substituted-cycloalkyl, -aryl, -heterocycle; n = 2-8; m = 0-1; q = 0-1; x = 0-1; p = 0-2; R1 independently = halo, CN, NO2, alkyl; R2 and R3 = independently H, halo, alkyl, etc.; R4 and R5 = independently = H, halo, alkylaryl, etc.; R6 and R7 = independently H, halo, alkyl, etc.; R8 = H, alkyl, alkylcycloalkyl, alkylaryl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as useful for the treatment of **liver X receptor** (**LXR**) mediated diseases. Thus, e.g., II was prepared by reductive amination of 2,2-diphenylethylamine with 2-chloro-3-trifluoromethylbenzaldehyde followed by alkylation with 3-bromo-1-propanol and Mitsunobo reaction with S-methyl-1H-pyrazol-3-ol. The **LXR**.alpha. and **LXR** β agonist activity of I was evaluated using Ligand Sensing Assay (LiSA)(data provided). I as **LXR** modulators should prove useful in treatment of cardiovascular disease, atherosclerosis, inflammation, and cholesterol absorption and transport.

ST isoxazole deriv prepn **liver X receptor** modulator; pyrazole deriv prepn **liver X receptor** modulator

IT Steroid **receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**LXR**.alpha. (**liver X receptor** α); preparation of pyrazole and isoxazole derivs. as modulators of **liver X receptors**)

IT Steroid **receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**LXR**.beta. (**liver X receptor** β); preparation of pyrazole and isoxazole derivs. as modulators of **liver X receptors**)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of pyrazole and isoxazole derivs. as modulators of **liver X receptors**)

IT Anti-inflammatory agents
(nonsteroidal; preparation of pyrazole and isoxazole derivs. as modulators of **liver X receptors**)

IT Anticholesteremic agents
Atherosclerosis
Cardiovascular agents
Cardiovascular system, disease
Human
Hypercholesterolemia
Inflammation
(preparation of pyrazole and isoxazole derivs. as modulators of **liver X receptors**)

IT Biological transport
(uptake, cholesterol; preparation of pyrazole and isoxazole derivs. as modulators of **liver X receptors**)

IT 847946-65-0P 847946-68-3P 847946-69-4P **847946-75-2P** **847946-76-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole and isoxazole derivs. as modulators of **liver X receptors**)

IT 847946-66-1P 847946-67-2P **847946-72-9P** **847946-73-0P** **847946-74-1P** 847946-77-4P 847946-78-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of pyrazole and isoxazole derivs. as modulators of **liver X receptors**)

IT 108-18-9, Diisopropylamine 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions 123-90-0, Thiomorpholine 617-89-0, Furan-2-yl methylamine 627-18-9 3963-62-0, 2,2-Diphenylethylamine 4344-87-0, 5-Methyl-1H-pyrazol-3-ol 10068-07-2 93118-03-7, 2-Chloro-3-trifluoromethylbenzaldehyde
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazole and isoxazole derivs. as modulators of **liver X receptors**)

IT 405911-35-5P 610319-03-4P 847946-70-7P 847946-71-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole and isoxazole derivs. as modulators of **liver X receptors**)

IT 278596-98-8 363593-56-0
RL: PRP (Properties)
(unclaimed sequence; preparation of 5-membered heterocyclic derivs. as modulators of **liver X receptors**)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Collins; WO 0224632 A2 2002 HCAPLUS

IT **847946-75-2P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole and isoxazole derivs. as modulators of **liver X receptors**)

RN 847946-75-2 HCAPLUS
CN 5-Isoxazoleacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



L41 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:232578 HCAPLUS
DN 142:316693
ED Entered STN: 17 Mar 2005
TI Preparation of indole derivatives as modulators of **liver X receptors**
IN Hoang, Tram H.; **Thompson, Scott Kevin**; Washburn, David G.
PA **Smithkline Beecham Corporation, USA**
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 27-11 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005023196	A2	20050317	WO 2004-US28798	20040903
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-499659P	P	20030903		
	US 2003-500295P	P	20030904		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005023196	ICM	A61K

OS MARPAT 142:316693

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = -(O)x; X = H, alkyl, alkenyl, etc.; Y = -O-, -S-, -N(R8)-, etc.; W1 = (un)substituted-cycloalkyl, -aryl, -heterocycle; W2 = H, halo, alkynyl, etc.; W3 = H, halo, (un)substituted alkyl, etc.; Q = (un)substituted-cycloalkyl, -aryl, -heterocycle; n = 2-8; m = 0-1; q = 0-1; x = 0-1; p = 0, or p is 1 and R1 = oxo, or p is 1 or 2 and each R1 independently = halo, CN, NO2, alkyl; R2 and R3 = independently H, halo, alkyl, etc.; R4 and R5 = independently = H, halo, alkylaryl, etc.; R6 and R7 = independently H, alkyl, alkenyl, alkynyl, etc.; R8 = H, alkyl, alkylcycloalkyl, alkylaryl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as useful for the treatment of **liver X receptor** (**LXR**) mediated diseases. Thus, e.g., II was prepared by reductive amination of 2,2-diphenylethylamine with 2-chloro-3-trifluoromethylaldehyde followed by an alkylation/Williamson's etherification sequence. The **LXR** α and **LXR**.beta. agonist activity of I was evaluated using Ligand Sensing Assay (LiSA)(data provided). I as **LXR** modulators should prove useful in treatment of cardiovascular disease, atherosclerosis, inflammation, and cholesterol absorption and transport.

ST indole deriv prepn **liver X receptor** modulator

IT Steroid **receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**LXR**.alpha. (**liver X receptor** α); preparation of indole derivs. as modulators of **liver X receptors**)

IT Steroid **receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**LXR**.beta. (**liver X receptor** β); preparation of indole derivs. as modulators of **liver X receptors**)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of indole derivs. as modulators of

liver X receptors)

IT Anti-inflammatory agents
(nonsteroidal; preparation of indole derivs. as modulators of **liver X receptors)**

IT Anticholesteremic agents
Atherosclerosis
Cardiovascular agents
Cardiovascular system, disease
Human
Hypercholesterolemia
Inflammation
(preparation of indole derivs. as modulators of **liver X receptors)**

IT Biological transport
(uptake, cholesterol; preparation of indole derivs. as modulators of **liver X receptors)**

IT 847990-39-0P 847990-40-3P **847990-41-4P 847990-43-6P 847990-44-7P 847990-45-8P 847990-46-9P 847990-47-0P** 847990-69-6P 847990-70-9P 847990-72-1P 847990-76-5P 847990-81-2P 847990-85-6P 847990-87-8P 847990-89-0P 847990-91-4P 847990-94-7P 847990-99-2P 847991-03-1P 847991-17-7P 847991-18-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indole derivs. as modulators of **liver X receptors)**

IT **847990-42-5P** 847990-48-1P 847990-49-2P 847990-50-5P 847990-51-6P 847990-52-7P 847990-53-8P 847990-54-9P 847990-55-0P 847990-56-1P 847990-57-2P 847990-58-3P 847990-59-4P 847990-60-7P 847990-61-8P 847990-62-9P 847990-63-0P 847990-64-1P 847990-65-2P 847990-66-3P 847990-67-4P 847990-68-5P 847990-73-2P 847990-77-6P 847990-82-3P 847990-83-4P 847990-86-7P 847990-88-9P 847990-90-3P 847990-92-5P 847990-95-8P 847991-00-8P **847991-04-2P** 847991-05-3P 847991-08-6P 847991-11-1P 847991-14-4P 847991-19-9P 847991-20-2P 847991-21-3P 847991-22-4P 847991-23-5P 847991-24-6P 847991-25-7P 847991-26-8P 847991-27-9P 847991-28-0P 847991-29-1P 847991-30-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. as modulators of **liver X receptors)**

IT 98-59-9, p-Toluenesulfonyl chloride 100-46-9, Benzylamine, reactions 106-94-5, 1-Bromopropane 106-95-6, Allyl bromide, reactions 109-64-8, 1,3-Dibromopropane 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions 123-90-0, Thiomorpholine 331-64-6, 2-Fluoro-4-methoxybenzaldehyde 351-54-2, 3-Fluoro-4-methoxybenzaldehyde 613-45-6 617-89-0, Furan-2-yl-methylamine 627-18-9 1953-54-4, 5-Hydroxyindole 2380-94-1, 4-Hydroxyindole 3963-62-0, 2,2-Diphenylethylamine 5417-17-4, 2-Chloro-3,4-dimethoxybenzaldehyde 10147-36-1, Propanesulfonyl chloride 10147-37-2, Isopropylsulfonyl chloride 17596-79-1, (S)-2-Phenylpropylamine 24621-61-2 28163-64-6 67515-60-0, 4-Fluoro-3-trifluoromethylbenzaldehyde 93118-03-7, 2-Chloro-3-trifluoromethylbenzaldehyde 98244-48-5, (S)-3-Bromo-2-methyl-propanol 112641-20-0, 2-Fluoro-3-trifluoromethylbenzaldehyde
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indole derivs. as modulators of **liver X receptors)**

IT 70260-94-5P 82614-88-8P 405911-35-5P 609772-05-6P 609772-13-6P

610319-03-4P 612498-19-8P 612499-61-3P 847990-74-3P 847990-75-4P
847990-78-7P 847990-79-8P 847990-80-1P 847990-84-5P 847990-93-6P
847990-96-9P 847990-98-1P 847991-06-4P 847991-07-5P 847991-09-7P
847991-10-0P 847991-12-2P 847991-13-3P 847991-15-5P 847991-16-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indole derivs. as modulators of **liver X receptors**)

IT **847990-41-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indole derivs. as modulators of **liver X receptors**)

RN 847990-41-4 HCAPLUS

CN Thiomorpholine, 4-[[4-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-1H-indol-1-yl]acetyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:796427 HCAPLUS

DN 139:323535

ED Entered STN: 10 Oct 2003

TI Preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivatives as modulating agents for **liver X receptors** (**LXR**)

IN **Thompson, Scott K.**; **Frazee, James S.**; **Kallander, Lara S.**; **Ma, Chun**; **Marino, Joseph P.**; **Neeb, Michael J.**; Bhat, Ajita; Mcatee, John Jeffrey; Stavenger, Robert A.

PA **Smithkline Beecham Corporation, USA**

SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2003082205 A2 20031009 WO 2003-US9450 20030326
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2005113580 A1 20050526 US 2003-508894 20030326
PRAI US 2002-368425P P 20020327
WO 2003-US9450 W 20030326
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003082205	ICM	A61K
US 2005113580	NCL	546/268.100; 546/335.000; 560/024.000; 562/043.000; 558/410.000; 562/450.000

OS MARPAT 139:323535
GI



I

AB The title compds. (I) [X = C1-8 alkyl, halo, each (un)substituted OH, NH2, NHCONH2, SO2NH2, CO2H, or C(:NH)NH2, 5 or 6-membered heterocyclyl, etc.; or X and R3 together with their bonded atoms form alkylenedioxy; Z = (un)substituted CH or N; when Z = (un)substituted CH, p1 = 0-4 and q1 = 0-1; when Z = N, p1 = 0-3 and q1 = 0; Y = O, S, each (un)substituted NH or CH2; W1 = C1-6 alkyl, C3-8 cycloalkyl, aryl, heterocyclyl, etc.; W2 = H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, each N, S, or O-(un)substituted C0-6 alkyl-NH2, C0-C6 alkyl-SH, C0-6 alkyl-OH, C0-6 alkyl-CO2H, etc.; W3 = H, halo, C1-6 alkyl, each N, S, or O-(un)substituted C0-6 alkyl-NH2, C0-6 alkyl-SH, C0-6 alkyl-OH, or C0-6 alkyl-CO2H, etc.; p = 0-8; n = 2-8; m, q, q1 = 0, 1; R1, R2 = H, halo, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, each N-, O-, or S-(un)substituted C0-6 alkyl-NH2 C0-6 alkyl-OH, or C0-6 alkyl-SH, heterocyclyl-C1-C6 alkyl, aryl-C1-6 alkyl, C3-7 cycloalkyl-C1-C6 alkyl, etc.; or CR1R2 forms a 3-5 membered carbocyclic or heterocyclic ring; R3 = halo, cyano, nitro, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, aryl-C0-6 alkyl, heterocyclyl-C0-6 alkyl etc.; R4, R5 = H, halo, C1-6 alkyl, heterocyclyl-C0-6 alkyl, aryl-C0-6 alkyl, C3-7 cycloalkyl-C0-6 alkyl; R6, R7, R8, R9 = H, halo, C1-6 alkyl, heterocyclyl-C0-6 alkyl, aryl-C0-6 alkyl, C3-7 cycloalkyl-C0-6 alkyl, etc.] or pharmaceutically acceptable salts or solvates thereof are prepared Many specific compds. are claimed. Also disclosed are pharmaceutical compns. containing the compds. I. The compds. I, salts and solvates of this invention are useful as **LXR** agonists for the prevention or treatment of **LXR**-mediated diseases such as cardiovascular disease, atherosclerosis, inflammation or as a medicament for increasing reverse cholesterol transport or inhibiting cholesterol

absorption.

ST phenoxypropylbenzylamine prepn agonist **liver X receptor**; pyridyloxypropylbenzylamine prepn modulator **LXR** ; cardiovascular disease treatment prevention phenoxypropylbenzylamine pyridyloxypropylbenzylamine prepn; atherosclerosis treatment prevention phenoxypropylbenzylamine pyridyloxypropylbenzylamine prepn; inflammation treatment prevention phenoxypropylbenzylamine pyridyloxypropylbenzylamine prepn

IT Steroid **receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**LXR** (**liver X receptor**); preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for **liver X receptors** (**LXR**) for prevention or treatment of **LXR**-mediated diseases)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for **liver X receptors** (**LXR**) for prevention or treatment of **LXR**-mediated diseases)

IT Anti-inflammatory agents
Atherosclerosis
Cardiovascular agents
Cardiovascular system, disease
Inflammation
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for **liver X receptors** (**LXR**) for prevention or treatment of **LXR**-mediated diseases)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(increasing reverse cholesterol transport or inhibiting cholesterol absorption; preparation of [3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for **liver X receptors** (**LXR**))

IT 609772-07-8P 609772-11-4P 612498-41-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for **liver X receptors** (**LXR**) for prevention or treatment of **LXR**-mediated diseases)

IT 393-49-7P, 2-Trifluoromethyl-5-nitroaniline 632-02-0P 938-95-4P, 2-(4-Chlorophenyl)propionic acid 942-54-1P, 2-(4-Methoxyphenyl)propionic acid 2184-85-2P 4442-83-5P, 2-Cyclohexyl-2-phenylethanol 4442-89-1P 13027-73-1P 13062-93-6P, 2-(4-Methoxyphenyl)propylamine hydrochloride 14320-58-2P 19962-06-2P 20334-70-7P, 2-(3-Chlorophenyl)propionic acid 25912-16-7P, 3-Pyrrolidin-1-ylphenol 28387-66-8P 30988-91-1P 31007-10-0P 32040-07-6P, 1-(3-Methoxyphenyl)pyrrolidine 35022-33-4P, Methyl 2,2-dimethyl-3-(3-hydroxyphenyl)propionate 42058-59-3P, Methyl 3-hydroxyphenylacetate 58955-78-5P, N-Methyl-3-nitrobenzenesulfonamide 62969-42-0P, (3-Benzyloxyphenyl)acetic acid methyl ester 63362-05-0P 65292-90-2P 65857-58-1P 72551-60-1P 72551-61-2P 73415-84-6P 78103-77-2P, Methyl 2-phenyl-4-methyl-4-pentenoate 78592-82-2P 81270-37-3P 91061-46-0P 99329-55-2P, 4-(3-Methoxyphenyl)piperidine 99329-65-4P 99329-68-7P, 1-Benzyl-4-(3-methoxyphenyl)piperidin-4-ol 140232-81-1P 156450-01-0P 198627-86-0P 228579-12-2P, Methyl [3-(3-bromopropoxy)phenyl]acetate 394202-85-8P **405910-78-3P** 405911-17-3P 405911-26-4P 405911-35-5P 453560-74-2P 459434-40-3P

609772-10-3P 609772-14-7P 610317-98-1P 610317-99-2P 610318-03-1P
610318-44-0P 610318-97-3P 610318-99-5P 610319-00-1P 610319-01-2P
610319-02-3P 610319-03-4P 610319-19-2P 610319-22-7P 610319-23-8P
610319-24-9P 610319-26-1P 612498-25-6P 612498-26-7P 612498-27-8P
612498-28-9P 612498-29-0P 612498-30-3P 612498-31-4P 612498-32-5P
612498-33-6P 612498-34-7P 612498-35-8P 612498-36-9P 612498-40-5P
612498-42-7P 612498-43-8P 612498-44-9P, (2-Chloro-3-
trifluoromethylbenzyl)(2-cyclohexyl-2-phenylethyl)[3-[3-[(1-ethoxymethyl-
1H-1,2,3,4-tetrazol-5-yl)methyl]phenoxy]propyl]amine 612498-45-0P,
(2-Chloro-3-trifluoromethylbenzyl)(2-cyclohexyl-2-phenylethyl)[3-[3-[(2-
ethoxymethyl-2H-1,2,3,4-tetrazol-5-yl)methyl]phenoxy]propyl]amine
612498-47-2P 612498-48-3P 612498-49-4P 612498-50-7P 612498-51-8P
612498-52-9P 612498-53-0P 612498-54-1P 612498-55-2P 612498-56-3P
612498-57-4P 612498-58-5P 612498-59-6P 612498-60-9P 612498-62-1P
612498-63-2P 612498-64-3P 612498-65-4P 612498-66-5P 612498-67-6P
612498-68-7P 612498-69-8P 612498-70-1P 612498-71-2P 612498-72-3P
612498-73-4P 612498-74-5P 612498-75-6P 612498-76-7P 612498-77-8P
612498-79-0P 612498-80-3P 612498-82-5P 612498-83-6P 612498-84-7P
612498-86-9P 612498-87-0P 612498-88-1P 612498-89-2P 612498-90-5P
612498-91-6P 612498-93-8P 612498-95-0P 612498-96-1P 612498-97-2P
612498-98-3P 612498-99-4P 612499-00-0P 612499-01-1P 612499-02-2P
612499-03-3P 612499-05-5P 612499-06-6P, 2-[3-[3-[[2-Chloro-3-
(trifluoromethyl)benzyl]-(2,2-diphenylethyl)amino]propoxy]phenyl]-N-
ethylacetamide hydrochloride 612499-07-7P 612499-08-8P 612499-09-9P
612499-10-2P 612499-13-5P 612499-14-6P 612499-15-7P 612499-16-8P
612499-17-9P 612499-18-0P 612499-19-1P 612499-20-4P 612499-21-5P
612499-22-6P 612499-23-7P 612499-25-9P 612499-26-0P 612499-27-1P
612499-28-2P 612499-29-3P 612499-30-6P 612499-31-7P 612499-32-8P
612499-33-9P 612499-34-0P 612499-35-1P 612499-36-2P 612499-37-3P
612499-38-4P 612499-39-5P 612499-40-8P 612499-41-9P 612499-42-0P
612499-43-1P 612499-44-2P 612499-55-5P 612499-56-6P 612499-57-7P
612499-58-8P 612499-59-9P 612499-60-2P 612499-61-3P 612499-62-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of N-[3-(2-pyridyloxy or
phenoxy)propyl]benzylamine derivs. as modulating agents for
liver X receptors (**LXR**) for
prevention or treatment of **LXR**-mediated diseases)

IT 609772-09-0P 612498-39-2P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)
(intermediate; preparation of N-[3-(2-pyridyloxy or
phenoxy)propyl]benzylamine derivs. as modulating agents for
liver X receptors (**LXR**) for
prevention or treatment of **LXR**-mediated diseases)

IT 612499-46-4P 612499-48-6P 612499-50-0P 612499-52-2P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as
modulating agents for **liver X receptors** (
LXR) for prevention or treatment of **LXR**-mediated
diseases)

IT 612495-16-6P 612495-17-7P 612495-23-5P 612495-46-2P 612495-65-5P
612498-19-8P 612498-37-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as

modulating agents for **liver X receptors** (**LXR**) for prevention or treatment of **LXR**-mediated diseases)

IT 36611-40-2P 36665-82-4P 68505-16-8P 74771-89-4P 78651-13-5P
78651-14-6P 80084-95-3P 80084-96-4P 83987-10-4P 83987-36-4P
83987-43-3P 83987-61-5P 93788-43-3P 217098-62-9P 217098-65-2P
317360-11-5P 329774-24-5P 329774-26-7P 329774-28-9P 609772-06-7P
609772-13-6P 609772-15-8P 609772-16-9P 612494-88-9P 612494-89-0P
612494-90-3P 612494-91-4P 612494-92-5P 612494-93-6P 612494-94-7P
612494-95-8P 612494-96-9P 612494-97-0P 612494-98-1P 612494-99-2P
612495-00-8P 612495-01-9P 612495-02-0P 612495-03-1P 612495-04-2P
612495-05-3P 612495-06-4P 612495-07-5P 612495-08-6P 612495-09-7P
612495-10-0P 612495-11-1P 612495-12-2P 612495-13-3P 612495-14-4P
612495-15-5P 612495-18-8P 612495-19-9P 612495-20-2P 612495-21-3P
612495-22-4P, N-(2-Chlorophenyl)-N'-[3-[3-[(2-chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]urea hydrochloride 612495-24-6P 612495-25-7P 612495-26-8P 612495-27-9P
612495-28-0P, N'-(2-Chlorophenyl)-N-[3-[3-[(2-chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-methylurea hydrochloride 612495-29-1P 612495-30-4P,
N-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N'-(3,5-dimethoxyphenyl)-N-methylurea hydrochloride 612495-31-5P 612495-32-6P 612495-33-7P 612495-34-8P
612495-35-9P 612495-36-0P 612495-37-1P 612495-38-2P 612495-39-3P
612495-40-6P 612495-41-7P 612495-42-8P 612495-43-9P 612495-44-0P
612495-45-1P 612495-47-3P 612495-48-4P 612495-49-5P 612495-50-8P
612495-51-9P 612495-52-0P 612495-53-1P 612495-54-2P 612495-55-3P
612495-56-4P 612495-57-5P 612495-58-6P 612495-59-7P 612495-60-0P
612495-61-1P 612495-62-2P 612495-63-3P 612495-64-4P 612495-66-6P
612495-67-7P 612495-68-8P 612495-69-9P 612495-70-2P 612495-71-3P
612495-72-4P 612495-73-5P 612495-74-6P 612495-75-7P 612495-76-8P
612495-77-9P 612495-78-0P 612495-79-1P 612495-80-4P 612495-81-5P
612495-82-6P 612495-83-7P 612495-84-8P 612495-85-9P 612495-86-0P
612495-87-1P 612495-88-2P 612495-89-3P 612495-90-6P 612495-91-7P
612495-92-8P 612495-93-9P 612495-94-0P 612495-95-1P 612495-96-2P
612495-97-3P 612495-98-4P 612495-99-5P 612496-00-1P 612496-01-2P
612496-02-3P 612496-03-4P 612496-04-5P 612496-06-7P 612496-07-8P
612496-08-9P 612496-09-0P 612496-10-3P 612496-12-5P 612496-13-6P
612496-14-7P 612496-15-8P 612496-16-9P 612496-17-0P 612496-18-1P
612496-19-2P 612496-20-5P 612496-21-6P 612496-22-7P 612496-23-8P
612496-24-9P 612496-25-0P 612496-26-1P 612496-27-2P 612496-28-3P
612496-29-4P 612496-30-7P 612496-31-8P 612496-32-9P 612496-33-0P
612496-34-1P 612496-35-2P 612496-36-3P 612496-37-4P 612496-38-5P
612496-39-6P 612496-40-9P 612496-42-1P 612496-43-2P 612496-44-3P
612496-45-4P 612496-46-5P 612496-47-6P 612496-48-7P 612496-49-8P
612496-50-1P 612496-51-2P 612496-52-3P 612496-53-4P 612496-54-5P
612496-55-6P 612496-56-7P 612496-57-8P 612496-58-9P 612496-59-0P
612496-60-3P 612496-61-4P 612496-62-5P 612496-63-6P 612496-64-7P
612496-65-8P 612496-66-9P 612496-67-0P 612496-68-1P 612496-69-2P
612496-70-5P 612496-71-6P 612496-72-7P 612496-73-8P 612496-74-9P
612496-75-0P 612496-76-1P 612496-77-2P 612496-78-3P 612496-79-4P
612496-80-7P 612496-81-8P 612496-82-9P 612496-83-0P 612496-84-1P
612496-85-2P 612496-86-3P 612496-87-4P 612496-88-5P 612496-89-6P
612496-90-9P 612496-91-0P 612496-92-1P 612496-93-2P 612496-94-3P
612496-95-4P 612496-96-5P 612496-97-6P 612496-98-7P 612496-99-8P
612497-00-4P 612497-01-5P 612497-02-6P 612497-03-7P 612497-04-8P
612497-05-9P 612497-06-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for **liver X receptors** (**LXR**) for prevention or treatment of **LXR**-mediated diseases)

IT 612497-07-1P 612497-08-2P 612497-09-3P 612497-10-6P 612497-11-7P 612497-12-8P 612497-13-9P 612497-14-0P 612497-15-1P, N-(2-Chlorophenyl)-N'-[3-[3-[(2-chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]urea 612497-16-2P 612497-17-3P 612497-18-4P 612497-19-5P, N-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-methylbenzenesulfonamide 612497-20-8P, N'-(2-Chlorophenyl)-N-[3-[3-[(2-chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N-methylurea 612497-21-9P 612497-22-0P, N-[3-[3-[(2-Chloro-3-trifluoromethylbenzyl)(2,2-diphenylethyl)amino]propoxy]phenyl]-N'-(3,5-dimethoxyphenyl)-N-methylurea 612497-23-1P 612497-24-2P 612497-25-3P 612497-26-4P 612497-27-5P 612497-28-6P 612497-29-7P 612497-30-0P 612497-31-1P 612497-32-2P 612497-33-3P 612497-34-4P 612497-35-5P 612497-36-6P 612497-37-7P 612497-38-8P 612497-39-9P 612497-40-2P 612497-41-3P 612497-42-4P 612497-43-5P 612497-44-6P 612497-45-7P 612497-46-8P 612497-47-9P 612497-48-0P 612497-49-1P 612497-50-4P 612497-51-5P 612497-52-6P 612497-53-7P 612497-54-8P 612497-55-9P 612497-56-0P 612497-57-1P 612497-58-2P 612497-59-3P 612497-60-6P 612497-61-7P 612497-62-8P 612497-63-9P 612497-64-0P 612497-65-1P 612497-66-2P 612497-67-3P 612497-68-4P 612497-69-5P 612497-70-8P 612497-71-9P 612497-72-0P 612497-73-1P 612497-74-2P 612497-75-3P 612497-76-4P 612497-77-5P 612497-78-6P 612497-79-7P 612497-80-0P 612497-81-1P 612497-82-2P 612497-83-3P 612497-84-4P 612497-85-5P 612497-86-6P 612497-87-7P 612497-88-8P 612497-89-9P 612497-90-2P 612497-91-3P 612497-92-4P 612497-93-5P 612497-94-6P 612497-95-7P 612497-96-8P 612497-97-9P, N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)[3-[3-(2-methyl-2-aminopropyl)phenoxy]propyl]amine 612497-98-0P 612497-99-1P 612498-00-7P 612498-01-8P 612498-02-9P 612498-03-0P 612498-04-1P 612498-05-2P 612498-06-3P 612498-07-4P 612498-08-5P 612498-09-6P 612498-10-9P 612498-11-0P 612498-12-1P 612498-13-2P 612498-14-3P 612498-15-4P 612498-16-5P 612498-17-6P 612498-18-7P 612498-20-1P 612498-21-2P 612498-22-3P 612498-23-4P, 2-(2-Chloro-3-trifluoromethylbenzylamino)-1-phenylethanol 612498-24-5P 612498-46-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for **liver X receptors** (**LXR**) for prevention or treatment of **LXR**-mediated diseases)

IT 79-03-8, Propanoyl chloride 95-92-1, Diethyl oxalate 513-36-0, Isobutyl chloride 13831-31-7, Acetoxyacetyl chloride 55458-67-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for **liver X receptors** (**LXR**) for prevention or treatment of **LXR**-mediated diseases)

IT 50-00-0, Formaldehyde, reactions 64-04-0, Phenethylamine 64-19-7, Acetic acid, reactions 65-85-0, Benzoic acid, reactions 67-64-1, Acetone, reactions 74-88-4, Methyl iodide, reactions 74-89-5, Methylamine, reactions 75-03-6, Iodoethane 75-04-7, Ethylamine, reactions 75-07-0, Acetaldehyde, reactions 75-25-2, Bromoform 75-31-0, Isopropylamine, reactions 75-36-5, Acetyl chloride 75-90-1, 2,2,2-Trifluoroacetaldehyde 78-81-9, Isobutylamine 78-84-2, Isobutyraldehyde 79-31-2, Isobutyric acid 83-13-6, Diethyl

phenylmalonate 88-15-3, 2-Acetylthiophene 90-05-1, 2-Methoxyphenol 91-68-9, 3-Diethylaminophenol 93-25-4, o-Methoxyphenylacetic acid 95-48-7, o-Cresol, reactions 95-57-8, 2-Chlorophenol 96-17-3, 2-Methylbutyraldehyde 96-32-2, Methyl bromoacetate 97-96-1, 2-Ethylbutyraldehyde 98-09-9, Benzenesulfonyl chloride 98-17-9, 3-Trifluoromethylphenol 98-59-9, p-Toluenesulfonyl chloride 100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 100-83-4, 3-Hydroxybenzaldehyde 101-18-8, 3-Phenylaminophenol 104-01-8, p-Methoxyphenylacetic acid 107-10-8, n-Propylamine, reactions 108-39-4, m-Cresol, reactions 108-43-0, 3-Chlorophenol 108-46-3, 3-Hydroxyphenol, reactions 108-95-2, Phenol, reactions 109-01-3, 1-Methylpiperazine 109-64-8, 1,3-Dibromopropane 109-73-9, 1-Butylamine, reactions 110-52-1, 1,4-Dibromobutane 110-62-3, Valeraldehyde 110-91-8, Morpholine, reactions 118-31-0, 1-Naphthalenemethylamine 120-57-0, Benzo[1,3]dioxole-5-carboxaldehyde 120-80-9, 2-Hydroxyphenol, reactions 120-92-3, Cyclopentanone 121-51-7, 3-Nitrobenzenesulfonyl chloride 121-71-1 122-03-2, 4-Isopropylbenzaldehyde 123-08-0, 4-Hydroxybenzaldehyde 123-72-8, Butyraldehyde 123-75-1, Pyrrolidine, reactions 123-90-0, Thiomorpholine 124-40-3, Dimethylamine, reactions 124-63-0, Methanesulfonyl chloride 147-85-3, (S)-Pyrrolidine-2-carboxylic acid, reactions 150-19-6, 3-Methoxyphenol 150-76-5, 4-Methoxyphenol 344-25-2, (R)-Pyrrolidine-2-carboxylic acid 421-83-0, Trifluoromethanesulfonyl chloride 504-02-9, Cyclohexane-1,3-dione 527-69-5, Furan-2-carbonyl chloride 533-31-3, Sesamol 536-90-3, 3-Methoxyphenylamine 554-84-7, 3-Nitrophenol 590-86-3, Isovaleraldehyde 591-20-8, 3-Bromophenol 591-27-5, 3-Aminophenol 594-44-5, Ethanesulfonyl chloride 610-78-6, 4-Chloro-3-nitrophenol 611-20-1, 2-Cyanophenol 616-34-2, Glycine methyl ester 618-45-1, 3-Isopropylphenol 621-37-4 624-84-0, Formic hydrazide 627-18-9 627-30-5, 3-Chloro-1-propanol 627-31-6 628-21-7, 1,4-Diiodobutane 680-15-9, Methyl fluorosulfonyl difluoroacetate 873-62-1, 3-Cyanophenol 927-74-2, 1-Hydroxybut-3-yne 939-97-9, 4-tert-Butylbenzaldehyde 1122-62-9, 1-Pyridin-2-ylethanone 1458-98-6, 2-Methylallyl bromide 1489-69-6, Cyclopropylcarboxaldehyde 1648-99-3, 2,2,2-Trifluoroethanesulfonyl chloride 1722-12-9, 2-Chloropyrimidine 1878-65-5, m-Chlorophenylacetic acid 1878-66-6, p-Chlorophenylacetic acid 2444-36-2, o-Chlorophenylacetic acid 3188-13-4, Chloromethyl ethyl ether 3320-83-0, 2-Chlorophenyl isocyanate 3446-89-7, 4-Methylsulfanylbenzaldehyde 3894-09-5, 2-Cyclohexyl-2-phenylacetic acid 3963-62-0, 2,2-Diphenethylamine 4009-98-7, Methoxymethyltriphenylphosphonium chloride 4023-34-1, Cyclopropanecarbonyl chloride 4074-43-5, 3-Butylphenol 4187-38-6 4648-54-8, Trimethylsilyl azide 5458-84-4, 2-Iodo-5-nitroanisole 5460-31-1, 2-Methyl-3-nitrophenol 5473-12-1, (Methylamino)acetic acid methyl ester 6456-74-2 6622-91-9, 4-Pyridylacetic acid hydrochloride 7497-87-2 7568-93-6, 2-Amino-1-phenylethanol 10065-72-2 10130-74-2, 3-Methoxybenzenesulfonyl chloride 10147-36-1, Propane-1-sulfonyl chloride 10147-37-2, Isopropylsulfonyl chloride 13257-67-5, 2-Amino-2-methylpropionic acid methyl ester 16879-02-0, 6-Chloro-2-pyridinol 17596-79-1, (S)-(-)-2-Phenylpropylamine 18162-48-6, tert-Butyldimethylsilyl chloride 19438-10-9, Methyl 3-hydroxybenzoate 20967-96-8, 3-Benzyloxyphenylacetonitrile 21404-88-6 22868-60-6 24033-03-2, 3-Benzyloxybenzyl chloride 24424-99-5, Di-tert-butyl dicarbonate 25054-53-9, Piperonyloyl chloride 26628-22-8, Sodium azide 27292-49-5, 3-Morpholin-4-ylphenol 27292-50-8, 3-Piperidin-1-ylphenol 27298-98-2 27757-85-3, (Thiophen-2-ylmethyl)amine 28163-64-6, (R)-2-Phenylpropylamine 29668-44-8 30749-25-8, 3-Isobutylphenol 31466-44-1 31788-88-2 34577-88-3, 2-Phenylbutylamine 39226-96-5, 2-Chloro-3-trifluoromethylbenzylamine 41003-94-5, Diethylisocyanomethyl

phosphonate 50868-72-9 51558-14-6, 2-(4-Methoxyphenyl)propylamine 53332-80-2, [(1H-Imidazol-2-yl)methyl]amine 54132-76-2, 3,5-Dimethoxyphenyl isocyanate 55163-76-3, (R)-β-Methoxyphenethylamine 58971-10-1 59576-26-0 59817-32-2 73604-31-6, 3-Hydroxybenzylamine 75351-36-9 78659-23-1, 2-Trifluoromethyl-2-phenylacetaldehyde 79558-08-0, 3-Hydroxyphenoxyacetic acid methyl ester 82614-88-8 93118-03-7, 2-Chloro-3-trifluoromethylbenzaldehyde 97608-33-8 98244-48-5, (S)-(+)-3-Bromo-2-methyl-1-propanol 101144-99-4 108122-24-3 124312-73-8, (1-Methyl-1H-imidazol-2-yl)methylamine 135427-08-6, 4-Fluoro-3-methylbenzaldehyde 165047-24-5, 2,4,5-Trifluorobenzaldehyde 174472-00-5, (S)-β-Methoxyphenethylamine 196106-01-1 224450-48-0 258348-24-2 345893-26-7 405911-09-3 502649-73-2 610318-50-8 610318-54-2 612498-38-1, 3-(3-Benzyloxybenzyl)-3H-1,2,3,4-tetrazole 612498-61-0 612498-78-9 612498-81-4 612498-85-8, 2-Trifluoromethyl-5-nitrophenol 612498-92-7 612498-94-9 612499-04-4, (5-Bromothiophen-2-ylmethyl)amine 612499-11-3 612499-12-4 612499-24-8 612499-53-3 612499-54-4 612499-63-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for **liver X receptors** (**LXR**) for prevention or treatment of **LXR**-mediated diseases)

IT **405910-78-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for **liver X receptors** (**LXR**) for prevention or treatment of **LXR**-mediated diseases)

RN 405910-78-3 HCAPLUS
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



L41 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:287592 HCAPLUS
DN 137:41546
ED Entered STN: 18 Apr 2002
TI Identification of a Nonsteroidal **Liver X Receptor** Agonist through Parallel Array Synthesis of Tertiary Amines
AU Collins, Jon L.; Fivush, Adam M.; Watson, Michael A.; Galardi, Cristin M.; Lewis, Michael C.; Moore, Linda B.; Parks, Derek J.; Wilson, Joan G.; Tippin, Tim K.; Binz, Jane G.; Plunket, Kelli D.; Morgan, Daniel G.; Beaudet, Elizabeth J.; Whitney, Karl D.; Kliewer, Steven A.; Willson, Timothy M.
CS **GlaxoSmithKline, Research Triangle Park, NC, 27709, USA**
SO Journal of Medicinal Chemistry (2002), 45(10), 1963-1966
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society

DT Journal
LA English
CC 1-10 (Pharmacology)
Section cross-reference(s): 2
AB A potent, selective, orally active **liver x receptor** (**LXR**) agonist was identified from focused libraries of tertiary amines. GW3965 recruits the steroid **receptor** coactivator 1 to human **LXR**.alpha. in a cell-free ligand-sensing assay with an EC50 of 125 nM and profiles as a full agonist on hLXRα and hLXRβ in cell-based reporter gene assays with EC50's of 190 and 30 nM, resp. After oral dosing at 10 mg/kg to C57BL/6 mice, GW3965 increased expression of the reverse cholesterol transporter ABCA1 in the small intestine and peripheral macrophages and increased the plasma concns. of HDL cholesterol by 30%. GW3965 will be a valuable chemical tool to investigate the role of **LXR** in the regulation of reverse cholesterol transport and lipid metabolism
ST **liver X receptor** agonist tertiary amine
GW3965
IT Steroid **receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**LXR** (**liver X receptor**);
tertiary amine as nonsteroidal **liver X receptor** agonist which increases expression of reverse cholesterol transporter ABCA1 and plasma concns. of HDL cholesterol and has good oral bioavailability)
IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(high-d.; tertiary amine as nonsteroidal **liver X receptor** agonist which increases expression of reverse cholesterol transporter ABCA1 and plasma concns. of HDL cholesterol and has good oral bioavailability)
IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reverse cholesterol transporter ABCA1; tertiary amine as nonsteroidal **liver X receptor** agonist which increases expression of reverse cholesterol transporter ABCA1 and plasma concns. of HDL cholesterol and has good oral bioavailability)
IT Drug bioavailability
Human
(tertiary amine as nonsteroidal **liver X receptor** agonist which increases expression of reverse cholesterol transporter ABCA1 and plasma concns. of HDL cholesterol and has good oral bioavailability)
IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tertiary amine as nonsteroidal **liver X receptor** agonist which increases expression of reverse cholesterol transporter ABCA1 and plasma concns. of HDL cholesterol and has good oral bioavailability)
IT 77058-74-3, 24(S),25-Epoxycholesterol 293754-55-9, T0901317
405910-80-7 405910-82-9 405910-84-1
405910-93-2 405910-99-8 405911-02-6
405911-05-9 **405911-96-8 437991-36-1**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(tertiary amine as nonsteroidal **liver X receptor** agonist which increases expression of reverse cholesterol transporter ABCA1 and plasma concns. of HDL cholesterol and has good oral bioavailability)
IT 437991-39-4
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(tertiary amine as nonsteroidal **liver X receptor** agonist which increases expression of reverse cholesterol transporter ABCA1 and plasma concns. of HDL cholesterol and has good oral bioavailability)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Costet, P; J Biol Chem 2000, V275, P28240 HCAPLUS
(2) Repa, J; Genes Dev 2000, V14, P2819 HCAPLUS
(3) Repa, J; Science 2000, V289, P1524 HCAPLUS
(4) Schultz, J; Genes Dev 2000, V14, P2831 HCAPLUS
(5) Schwartz, K; Biochem Biophys Res Commun 2000, V274, P794 HCAPLUS
(6) Spencer, T; J Med Chem 2001, V44, P886 HCAPLUS
(7) Venkateswaran, A; Proc Natl Acad Sci U S A 2000, V97, P12097 HCAPLUS

IT **405910-80-7**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(tertiary amine as nonsteroidal **liver X receptor** agonist which increases expression of reverse cholesterol transporter ABCA1 and plasma concns. of HDL cholesterol and has good oral bioavailability)

RN 405910-80-7 HCAPLUS

CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



L41 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:240713 HCAPLUS

DN 136:294650

ED Entered STN: 28 Mar 2002

TI Preparation of substituted phenylacetamides and benzamides as agonists for **Liver X receptors (LXR)**

IN Collins, Jon Loren; Fivush, Adam M.; Maloney, Patrick Reed; Stewart, Eugene L.; Willson, Timothy Mark

PA **Glaxo Group Limited, UK**

SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM C07C237-00

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 2

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002024632	A2	20020328	WO 2001-US27622	20010906
WO 2002024632	A3	20020711		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

```
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    AU 2002011216        A5    20020402    AU 2002-11216          20010906
    EP 1318976           A2    20030618    EP 2001-979230         20010906
    EP 1318976           B1    20041124
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    JP 2004509161        T2    20040325    JP 2002-528647         20010906
    AT 283253            E     20041215    AT 2001-979230         20010906
    US 2004072868        A1    20040415    US 2003-380932         20030318
PRAI US 2000-233144P     P     20000918
    WO 2001-US27622      W     20010906
CLASS
 PATENT NO.      CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------  -----  ----------------------------------------------
 WO 2002024632   ICM    C07C237-00
 WO 2002024632   ECLA   C07C217/22; C07C217/58; C07C235/34; C07C235/46;
                        C07D207/09; C07D209/14; C07D211/58; C07D213/38;
                        C07D213/82H; C07D231/16; C07D233/54C2D4; C07D235/14;
                        C07D235/16; C07D239/52; C07D261/08; C07D277/28;
                        C07D307/52; C07D307/79B; C07D307/81; C07D309/20;
                        C07D317/58; C07D317/62; C07D317/64; C07D319/18;
                        C07D333/20
 JP 2004509161   FTERM  4C022/CA01; 4C022/KA01; 4C023/CA01; 4C033/AD06;
                        4C037/HA13; 4C037/HA23; 4C037/PA01; 4C037/PA09;
                        4C054/AA02; 4C054/CC09; 4C054/DD01; 4C054/EE01;
                        4C054/FF30; 4C055/AA01; 4C055/BA01; 4C055/BA02;
                        4C055/BA27; 4C055/BA42; 4C055/BB04; 4C055/BB08;
                        4C055/BB10; 4C055/CA01; 4C055/CA58; 4C055/DA01;
                        4C055/DA27; 4C055/DB04; 4C055/DB08; 4C056/AA01;
                        4C056/AB01; 4C056/AC01; 4C056/AD01; 4C056/AE03;
                        4C056/FA14; 4C062/BB09; 4C069/AA06; 4C084/AA17;
                        4C084/ZA36; 4C084/ZA45; 4C084/ZC33; 4C084/ZC41;
                        4C086/AA01; 4C086/AA03; 4C086/BA03; 4C086/BA06;
                        4C086/BA07; 4C086/BA13; 4C086/BA15; 4C086/BB02;
                        4C086/BC04; 4C086/BC13; 4C086/BC17; 4C086/BC21;
                        4C086/BC36; 4C086/BC38; 4C086/BC39; 4C086/BC42;
                        4C086/BC43; 4C086/BC67; 4C086/BC82; 4C086/MA01;
                        4C086/MA02; 4C086/MA04; 4C086/MA05; 4C086/NA14;
                        4C086/ZA36; 4C086/ZA45; 4C086/ZC33; 4C086/ZC41;
                        4C204/BB01; 4C204/BB09; 4C204/CB03; 4C204/DB13;
                        4C204/EB02; 4C204/FB01; 4C204/FB20; 4C204/GB01;
                        4C206/AA01; 4C206/AA03; 4C206/DA23; 4C206/DB15;
                        4C206/DB22; 4C206/DB43; 4C206/GA09; 4C206/GA22;
                        4C206/HA14; 4C206/KA01; 4C206/MA02; 4C206/MA05;
                        4C206/NA14; 4C206/ZA36; 4C206/ZA45; 4C206/ZC33;
                        4C206/ZC41; 4H006/AA01; 4H006/AB23; 4H006/BJ20;
                        4H006/BJ30; 4H006/BJ50; 4H006/BM10; 4H006/BM30;
                        4H006/BM71; 4H006/BN30; 4H006/BP30; 4H006/BS10;
                        4H006/BS30; 4H006/BT22; 4H006/BT32; 4H006/BU26;
                        4H006/BU32; 4H006/BU42; 4H006/BU46; 4H006/BV21;
                        4H006/BV25; 4H006/BV71; 4H006/QN30; 4H006/TA02;
                        4H006/TA04; 4H006/TB04
 US 2004072868   NCL    514/318.000; 514/317.000; 514/357.000; 514/567.000;
                        514/408.000; 514/620.000; 546/194.000; 546/228.000;
                        546/335.000; 546/276.400
                 ECLA   C07C217/22; C07D209/14; C07D211/58; C07D213/38;
                        C07D213/82H; C07D231/16; C07D233/54C2D4; C07D235/14;
                        C07D235/16; C07D239/52; C07D261/08; C07D277/28;
```

C07D307/52; C07D307/79B; C07D307/81; C07D309/20;
C07D317/58; C07D317/62; C07D317/64; C07D319/18;
C07D333/20; C07C217/58; C07C235/34; C07C235/46;
C07D207/09

OS MARPAT 136:294650

GI



I



II

AB The title compds. [I; X = OH, NH2; p = 0-6; R1, R2 = H, alkyl, alkoxy, thioalkyl; Z = CH, N; when Z = CH, k = 0-4; when Z = N, k = 0-3; R3 = halo, OH, alkyl, etc.; n = 2-8; q = 0-1; R4 = H, alkyl, alkenyl, alkenyloxy; A = cycloalkyl, aryl, 4-8 membered heterocycle, 5-6 membered heteroaryl; B = cycloalkyl, aryl] and their pharmaceutically acceptable salts, useful for the prevention or treatment of an **LXR** mediated disease and condition such as cardiovascular disease and atherosclerosis (no biol. data given), were prepared E.g., a solid phase synthesis of II was given.

ST **liver X receptor LXR** agonist
phenylacetamide benzamide prepn; cardiovascular phenylacetamide benzamide prepn; antiatherosclerotic phenylacetamide benzamide prepn; anticholesteremic phenylacetamide benzamide prepn

IT Steroid **receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**LXR** (**liver X receptor**),
LXR.beta.; preparation of substituted phenylacetamides and benzamides as agonists for **Liver X receptors** (**LXR**))

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of substituted phenylacetamides and benzamides as agonists for **Liver X receptors** (**LXR**))

IT Anticholesteremic agents
Cardiovascular agents
(preparation of substituted phenylacetamides and benzamides as agonists for **Liver X receptors (LXR)**)

IT **405910-78-3P 405910-80-7P 405910-82-9P**
405910-84-1P 405910-86-3P 405910-88-5P
405910-90-9P 405910-93-2P 405910-96-5P
405910-99-8P 405911-02-6P 405911-05-9P 405911-09-3P
405911-13-9P 405911-17-3P 405911-22-0P 405911-26-4P
405911-37-7P 405911-39-9P 405911-41-3P
405911-42-4P 405911-45-7P 405911-48-0P
405911-50-4P 405911-52-6P 405911-54-8P
405911-57-1P 405911-60-6P 405911-63-9P
405911-65-1P 405911-68-4P 405911-70-8P
405911-72-0P 405911-75-3P 405911-78-6P
405911-81-1P 405911-84-4P 405911-87-7P
405911-90-2P 405911-92-4P 405911-94-6P
405911-96-8P 405911-97-9P 405911-98-0P
405911-99-1P 405912-00-7P 405912-01-8P
405912-02-9P 405912-03-0P 405912-04-1P
405912-05-2P 405912-06-3P 405912-07-4P
405912-08-5P 405912-09-6P 405912-10-9P
405912-11-0P 405912-12-1P 405912-13-2P
405912-14-3P 405912-15-4P 405912-17-6P
405912-18-7P 405912-19-8P **405912-20-1P** 405912-21-2P
405912-22-3P 405912-23-4P 405912-24-5P
405912-25-6P 405912-26-7P 405912-27-8P
405912-28-9P 405912-29-0P 405912-30-3P
405912-31-4P 405912-32-5P 405912-33-6P
405912-34-7P 405912-35-8P 405912-36-9P
405912-37-0P 405912-38-1P 405912-39-2P
405912-40-5P 405912-41-6P 405912-42-7P
405912-43-8P 405912-44-9P 405912-45-0P
405912-46-1P 405912-47-2P 405912-48-3P
405912-49-4P 405912-50-7P 405912-51-8P
405912-52-9P 405912-53-0P 405912-54-1P
405912-55-2P 405912-56-3P 405912-57-4P
405912-58-5P 405912-59-6P 405912-60-9P
405912-61-0P 405912-62-1P 405912-63-2P
405912-64-3P 405912-65-4P 405912-66-5P
405912-67-6P 405912-68-7P 405912-69-8P
405912-70-1P 405912-71-2P 405912-72-3P
405912-73-4P 405912-74-5P 405912-75-6P
405912-76-7P 405912-77-8P 405912-78-9P
405912-79-0P 405912-80-3P 405912-81-4P
405912-82-5P 405912-83-6P 405912-84-7P
405912-85-8P 405912-86-9P 405912-87-0P
405912-88-1P 405912-89-2P 405912-90-5P
405912-91-6P 405912-92-7P 405912-93-8P
405912-94-9P 405912-95-0P 405912-96-1P
405912-97-2P 405912-98-3P 405912-99-4P
405913-00-0P 405913-01-1P 405913-02-2P
405913-03-3P 405913-04-4P 405913-05-5P
405913-06-6P 405913-07-7P 405913-08-8P
405913-09-9P 405913-10-2P 405913-11-3P
405913-12-4P 405913-13-5P 405913-14-6P
405913-15-7P 405913-16-8P 405913-18-0P
405913-19-1P 405913-20-4P 405913-21-5P
405913-22-6P 405913-23-7P 405913-24-8P
405913-26-0P 405913-27-1P 405913-28-2P

405913-29-3P 405913-31-7P 405913-32-8P
405913-33-9P 405913-34-0P 405913-35-1P
405913-36-2P 405913-37-3P 405913-38-4P
405913-39-5P 405913-40-8P 405913-41-9P
405913-42-0P 405913-43-1P 405913-44-2P
405913-45-3P 405913-46-4P 405913-47-5P
405913-48-6P 405913-49-7P 405913-50-0P
405913-51-1P 405913-52-2P 405913-53-3P
405913-54-4P 405913-55-5P 405913-56-6P
405913-57-7P 405913-58-8P 405913-59-9P
405913-60-2P 405913-61-3P 405913-62-4P
405913-63-5P 405913-64-6P 405913-65-7P
405913-66-8P 405913-67-9P 405913-68-0P
405913-69-1P 405913-70-4P 405913-71-5P
405913-72-6P 405913-73-7P 405913-74-8P
405913-75-9P 405913-76-0P 405913-77-1P
405913-78-2P 405913-79-3P 405913-80-6P
405913-81-7P 405913-82-8P 405913-83-9P
405913-84-0P 405913-85-1P 405913-86-2P
405913-87-3P 405913-88-4P 405913-89-5P
405913-90-8P 405913-91-9P 405913-92-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted phenylacetamides and benzamides as agonists for **Liver X receptors (LXR)**)

IT **405913-93-1P 405913-94-2P 405913-95-3P**
405913-96-4P 405913-97-5P 405913-98-6P
405913-99-7P 405914-00-3P 405914-01-4P
405914-02-5P 405914-03-6P 405914-04-7P
405914-05-8P 405914-06-9P 405914-07-0P
405914-08-1P 405914-09-2P 405914-10-5P
405914-11-6P 405914-12-7P 405914-13-8P
405914-14-9P 405914-15-0P 405914-16-1P
405914-17-2P 405914-18-3P 405914-19-4P
405914-20-7P 405914-21-8P 405914-22-9P
405914-23-0P 405914-24-1P 405914-25-2P
405914-26-3P 405914-27-4P 405914-29-6P
405914-31-0P 405914-33-2P 405914-35-4P
406680-56-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted phenylacetamides and benzamides as agonists for **Liver X receptors (LXR)**)

IT 123-11-5, 4-Methoxybenzaldehyde, reactions 606-99-5, Diphenylethylamine 621-37-4, 3-Hydroxyphenylacetic acid 627-18-9, 3-Bromo-1-propanol 42058-59-3, Methyl 3-hydroxyphenylacetate 93118-03-7, 2-Chloro-3-trifluoromethylbenzaldehyde 114774-44-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted phenylacetamides and benzamides as agonists for **Liver X receptors (LXR)**)

IT **228579-12-2P 405911-33-3P 405911-35-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted phenylacetamides and benzamides as agonists for **Liver X receptors (LXR)**)

IT 406858-29-5, 1: PN: WO0224632 SEQID: 3 unclaimed DNA 406858-30-8, 2: PN: WO0224632 SEQID: 4 unclaimed DNA 406858-31-9, 3: PN: WO0224632 SEQID: 5 unclaimed DNA

RL: PRP (Properties)
(unclaimed nucleotide sequence; preparation of substituted phenylacetamides and benzamides as agonists for **Liver X receptors (LXR)**)

IT 278596-98-8 363593-56-0
RL: PRP (Properties)
(unclaimed sequence; preparation of substituted phenylacetamides and benzamides as agonists for **Liver X receptors (LXR)**)

IT **405910-78-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted phenylacetamides and benzamides as agonists for **Liver X receptors (LXR)**)

RN 405910-78-3 HCAPLUS

CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



=>